

**(12) STANDARD PATENT  
(19) AUSTRALIAN PATENT OFFICE**

**(11) Application No. AU 2009248735 B2**

(54) Title  
**Expression vector encoding alphavirus replicase and the use thereof as immunological adjuvant**

(51) International Patent Classification(s)  
**A61K 39/39** (2006.01)      **A61P 37/04** (2006.01)

(21) Application No: **2009248735**      (22) Date of Filing: **2009.05.22**

(87) WIPO No: **WO09/141434**

(30) Priority Data

(31) Number **61/071,898**      (32) Date **2008.05.23**      (33) Country **US**

(43) Publication Date: **2009.11.26**  
(44) Accepted Journal Date: **2015.08.20**

(71) Applicant(s)  
**Fit Biotech Oy**

(72) Inventor(s)  
**Toots, Urve;Kaldma, Katrin;Sikut, Rein;Kiiver, Kaja;Ustav, Mart;Molder, Tarmo;Mannik, Andres**

(74) Agent / Attorney  
**Shelston IP, L 21 60 Margaret St, Sydney, NSW, 2000**

(56) Related Art  
**BREAKWELL L. et al, Journal of Virology, 2007, vol. 81(16), pg. 8677-8684**  
**WO 2008/119827 A1**  
**WO 1995/027044 A1**

WO 2009/141434 A4

## (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization  
International Bureau(43) International Publication Date  
26 November 2009 (26.11.2009)

(10) International Publication Number

WO 2009/141434 A4

(51) International Patent Classification:  
*A61K 39/39 (2006.01) A61P 37/04 (2006.01)*

(21) International Application Number:  
*PCT/EP2009/056240*

(22) International Filing Date:  
*22 May 2009 (22.05.2009)*

(25) Filing Language:  
*English*

(26) Publication Language:  
*English*

(30) Priority Data:  
*61/071,898 23 May 2008 (23.05.2008) US*

(71) Applicant (for all designated States except US): **FIT BIOTECH OY [FI/FI]**; Biokatu 8, FI-33520 Tampere (FI).

(72) Inventors; and

(75) Inventors/Applicants (for US only): **KIIVER, Kaja** [EE/EE]; A.H. Tammsaare 3-9, EE-51006 Tartu (EE). **SIKUT, Rein** [EE/EE]; Raja Street 1, EE-504 11 Tartu (EE). **TOOTS, Urve** [EE/EE]; Aardala 146-1, EE-504 15 Tartu (EE). **MÖLDER, Tarmo** [EE/EE]; Uus 13C-77, EE-504 15 Tartu (EE). **MÄNNIK, Andres** [EE/EE]; Näätsuse Street 9-4, EE-504 09 Tartu (EE). **USTAV, Mart** [EE/EE]; Jaama Street 58a, EE-50604 Tartu (EE). **KALDMA, Katrin** [EE/EE]; Herne 40-1, EE-51007 Tartu (EE).

(74) Agent: **VALEA AB**; Box 7086, S-103 87 Stockholm (SE).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

## Published:

- with international search report (Art. 21(3))
- with amended claims (Art. 19(1))
- with sequence listing part of description (Rule 5.2(a))

[Continued on next page]

(54) Title: EXPRESSION VECTOR ENCODING ALPHAVIRUS REPLICASE AND THE USE THEREOF AS IMMUNOLOGICAL ADJUVANT




Fig.1

(57) Abstract: The present invention relates to an alphaviral replicase, especially Semliki Forest Virus replicase, or an expression vector encoding an alphaviral replicase, said alphaviral replicase comprising RNA dependent RNA polymerase activity, for use as an immune system modulating adjuvant. The alphaviral replicase may be used in the combination with a vaccine providing an adjuvant function therein, which when present therein will generate an additional boost to the immune response in the subject to whom this combination is administered as compared to when the vaccine alone is administered to a subject in need thereof. The aim of the present invention is to provide an efficient and easy to administer, species-independent adjuvant which will provide advantages to the adjuvants used together with vaccines today.

WO 2009/141434 A4



---

Date of publication of the amended claims: 14 January 2010

**EXPRESSION VECTOR ENCODING ALPHAVIRUS REPLICASE AND THE USE THEREOF AS  
IMMUNOLOGICAL ADJUVANT**

**Technical field**

5 The present invention relates to the field of immunological tools and in particular to the field of vaccines and to adjuvants suitable for use in vaccine compositions.

**Background of the invention**

Any discussion of the prior art throughout the specification should in no way be considered as an admission that such prior art is widely known or forms part of common general knowledge in

10 the field.

The mammalian immune system has evolved in order to survive in the environment containing a large variety of microorganisms, which colonize them in a number of niches like skin, intestine, upper and lower respiratory tract, urogenital tract etc. Some of the niches like colon and skin are colonized constitutively by an endogenous microbiota, whereas other niches (internal organs

15 and lower respiratory tract) are normally kept sterile in an immunocompetent host. The effects of microorganism can be positive for the host, as is the case for the many intestinal symbiotic bacteria. In other cases, microbial colonization can be detrimental to the host. Such negative effects depend on the status of the host's immune system – certain pathogens (known as opportunistic pathogens) affect only immunocompromised individuals. The potential detrimental 20 effect of microbial infections has led to the evolution of variety of host-defence mechanisms. In jawed vertebrates, there are two types of defence: innate and adaptive immune responses. The main distinction between these is the receptor types used to recognize pathogens, the time-delay needed to launch the response and the presence/absence of memory. The two types of defence do not operate completely independently from each other. As seen in the below, innate 25 immune system sends specific signals to the adaptive immune system, helping to mount the response that is most efficient to the specific pathogen; and vice versa - adaptive immune response also activates some modules of the innate immune system.


*Innate immune response*

Innate immunity is always present in healthy individuals and its main function is to block the

30 entry of microbes and viruses as well as to provide a rapid elimination of pathogens that do succeed in entering the host tissues. It provides immediate protection for the multicellular organism.

Innate immune system is not a single entity. It is a collection of distinct modules or subsystems that appeared at different stages of evolution:

- Mucosal epithelia producing antimicrobial peptides, protecting the host from pathogen invasion;



- phagocytes with their anti-microbial mechanisms against intra- and extracellular bacteria;
- acute-phase proteins and complement system that are operating in the circulation and body fluids;
- natural killer cells, which are involved in killing virus infected cells;

5     • eosinophils, basophils and mast cells, which are involved against protection of multicellular parasites;

- type I interferons and proteins induced by them, which have a crucial role in defence against viruses.

10    The innate immune response is responsible for the early detection and destruction of invading microbes, and relies on a set of limited germ line-encoded pattern-recognition receptors (PRRs) for detection. To initiate immune responses, PRRs recognize pathogen-associated molecular patterns (PAMPs) and induce several extracellular activation cascades such as the complement pathway and various intracellular signalling pathways,

15    which lead to the inflammatory responses.

The innate immune system utilizes PRRs present in three different compartments: body fluids, cell membranes, and cytoplasm. The PRRs in the body fluids play major roles in PAMP opsonization, the activation of complement pathways, and in some cases the transfer of PAMPs to other PRRs. PRRs located on the cell membrane have diverse functions, such as the presentation of PAMPs to other PRRs, the promotion of microbial uptake by phagocytosis, and the initiation of major signalling pathways.

There are several functionally distinct classes of PRRs. The best characterized class is 25 Toll-like receptors (TLRs). These are transmembrane receptors that recognize viral nucleic acids and several bacterial products, including lipopolysaccharide and lipoteichoic acids and are the primary signal-generating PRRs (Akira, S 2006). In addition, cytoplasmic PRRs which can be grouped into three classes: interferon (IFN)-inducible proteins, caspase-recruiting domain (CARD) helicases, and nucleotide-binding 30 oligomerization domain (NOD)-like receptors (NLRs). Among the best studied IFN-induced antiviral proteins are the family of myxovirus resistance proteins (Mx), protein kinase R (PKR), oligoadenylate synthetase (2'-5' OAS). These antiviral proteins and CARD helicases such as RIG-I and Mda5 are involved in antiviral defence. In contrast, NLRs are mainly involved in antibacterial immune responses.

*Toll-like receptors (TLRs)*

TLRs are the best-characterized signal-generating receptors among PRRs. They initiate key inflammatory responses and also shape adaptive immunity. All TLRs (TLR1-11) known in mammals are type I integral membrane glycoproteins containing an extracellular leucine-rich repeat (LRR) domain responsible for ligand recognition and a cytoplasmic Toll-interleukine-1 receptor homology (TIR) domain required for initiating signalling. TLRs recognize quite diverse microbial components in bacteria, fungi, parasites, and viruses including nucleic acids. Although normally present at the plasma membrane to detect extracellular PAMPs, a few TLRs, including TLR3, TLR7, TLR8, and TLR9, recognize their ligands in the intracellular compartments such as endosomes. The latter TLRs share the ability of nucleic acid recognition, detecting dsRNA (TLR3), ssRNA (TLR7 in mice, TLR8 in humans), and non-methylated CpG DNA motifs (TLR9). TLRs initiate shared and distinct signalling pathways by recruiting different combinations of four TIR domain-containing adaptor molecules: MyD88, TIRAP, Trif, and TRAM. With the exception of TLR3, all the other TLRs recruit the myeloid differentiation factor 88 (MyD88), which is associated with members of the IL-receptor-associated kinase (IRAK) family (Mouldy Sioud 2006). These signalling pathways activate the transcription factors nuclear factor kappa B (NF- $\kappa$ B) and activator protein-1 (AP-1), which is common to all TLRs, leading to the production of inflammatory cytokines and chemokines. They also activate interferon regulatory factor-3 (IRF3) and/or IRF7 in TLRs 3, 4, 7, 8, and 9 which is a prerequisite for the production of type I interferons such as IFN- $\alpha$  and IFN- $\beta$  (For review Edwards et al 2007, Vercammen et al 2008, Medzitov R 2007).

In addition to direct activation of innate host-defence mechanisms, some PRRs are coupled to the induction of adaptive immune responses. T-and B-cells, the two main classes of cells in the adaptive immune system, express antigen binding receptors with random specificities and therefore recognize antigens that lack any intrinsic characteristics indicative of their origin. Therefore, T-and B-lymphocytes require instructions indicating the origin of the antigen they recognize. These instructions come from the innate immune system in the form of specialized signals inducible by PRRs. For T-cells this association is interpreted by dendritic cells. Type I interferons are involved in the activation and migration of dendritic cells (described in more details under Antiviral response). When activated dendritic cell migrates to the lymph node, they present the pathogen-derived antigens, together with PRR-induced signals, to T-cells. This results in T-cell activation and differentiation of T-helper (Th) cells into one of several types of effector Th-cells (Th1, Th2 and Th-17 cells). For instance TLR-engagement induces IL-12 production by dendritic cells, which directs Th cells to differentiate into Th1 cells. The type of effector response is

thus dictated by the innate immune system. In addition, type I interferons also regulate the function of cytotoxic T-cells and NK cells, either directly or indirectly by inducing IL-15 production.

5 The innate immune system also receives positive feedback signals from the adaptive immune system. For instance, effector Th-cells produce appropriate cytokines that activate specific modules of the innate immune system: macrophages are activated by cytokines (interferon- $\gamma$ ) secreted from Th1 cells, neutrophils are activated by Th-17 cells (interleukin-17) cells, mast cells and basophils are activated by Th2 cells (interleukin-4 and -5). Likewise, bound antibodies (IgG) activate complement proteins and help 10 phagocytosis by opsonizing pathogens.

#### *Adaptive Immune response*

15 The adaptive immune system uses a broad range of molecules for its activities. Some of these molecules are also used by the innate immune system, e.g. complement proteins, others, including antigen-specific B-cell and T-cell receptors, are unique to the adaptive immune system. The most important properties of the adaptive immune system, distinguishing it from innate immunity, are a fine specificity of B- and T-cell receptors, and a more slow development of the response and memory of prior exposure to antigen. The 20 latter property forms the basis of vaccination – priming of the immune system by attenuated pathogen, by selected components of the pathogen or by mimicking infection in other ways (e.g. by DNA-vaccine encoding selected antigens from a pathogen) results in the development of immunological memory, which triggers response more quickly and more efficiently upon pathogen encounter.

25 There are two types of adaptive immunity, humoral immunity and cell-mediated immunity. Humoral immunity is mediated by B-cells. Activated B-cells start to secrete the receptors into circulation and mucosal fluids, which in this case are referred to as antibodies (immunoglobulins). The genes encoding these receptors are assembled from variable and 30 constant fragments in the process of somatic recombination, prior to pathogen encounter, which yields a diverse repertoire of receptors. Each B- or T-cell is able to synthesize immunoglobulins or T-cell receptors of a single specificity that bind to a specific molecular structure (epitope). Antibodies bind noncovalently to specific antigens to immobilize them, render them harmless or tag the antigen for destruction (e.g. by complement proteins or 35 by macrophages) and removal by other components of the immune system.

Cell mediated immunity is mediated by T-cells. T-cells are key players in most adaptive immune responses. They participate directly in eliminating infected cells (CD8+ cytotoxic

T-cells) or orchestrate and regulate activity of other cells by producing various cytokines (CD4+ T-helper cells). Also the induction of antibodies by B-cells is in a majority of cases dependent on T-helper cells. The distinguished feature of T-cell antigen receptors is their inability to recognize soluble molecules – they can recognize peptide fragments of protein antigens on the cell surface bound to specialized peptide display molecules, called major histocompatibility complex (MHC). T-helper cells need MHC class II molecules for recognizing antigenic peptide fragments, and cytotoxic T-cells need MHC class I molecules. This feature enables T-cells to detect intracellular pathogens, which otherwise could remain undetected by the immune system, because short peptides (9-10 amino acids) from all proteins synthesized in eukaryotic cells (including peptides derived from pathogens) are exposed on the cell surface in the ‚peptide pockets‘ of MHC molecules. Adaptive immune response is initiated after pathogen capture by professional antigen presenting cells (APCs). Naive T-lymphocytes need to see antigens presented by MHC-antigens on APCs. These cells are present in all epithelia of the body, which is the interface between the body and external environment. In addition to that, APCs are present in smaller numbers in most other organs. APCs in the epithelia belong to the lineage of dendritic cells. In the skin, the epidermal dendritic cells are called Langerhans cells. Dendritic cells capture antigens of microbes that enter the epithelium, by the process of phagocytosis or pinocytosis. After antigen capture dendritic cells round up and lose their adhesiveness for the epithelium, they leave the epithelium and migrate via lymphatic vessels to the lymph node draining that epithelium. During the process of migration the dendritic cells mature into cells capable of stimulating T-cells. This maturation is reflected in increased synthesis and stable expression of MHC molecules, which display antigen to T-cells, and other molecules, co-stimulators, that are required for full T-cell responses. The result of this sequence of events is that the protein antigens of microbes are transported to the specific regions of lymph nodes where the antigens are most likely to encounter T-lymphocytes. Naive T-lymphocytes continuously recirculate through lymph nodes, and it is estimated that every naive T-cell in the body may cycle through some lymph nodes at least once a day. Thus, initial encounter of T-cells with antigens happens in lymph nodes and this is called priming. Primed CD4+ T-helper cells start secreting a variety of cytokines, which help other cells of the immune system to respond. Dendritic cells carry to the lymph nodes not only peptide fragments from pathogens, but also PRR-induced signals sent from innate immune system (as mentioned above, type I IFNs influence activation and differentiation of dendritic cells). Dendritic cells convert this information into activation of specific clones of T-cells (that recognize pathogenic peptides) and differentiation of suitable type of T-helper cells. Priming of CD8+ T-cells is also performed by dendritic cells, but further proliferation and maturation of

CD8+ T-cells into fully functional killer cells depends on cytokines secreted by T-helper cells.

5 Taken together, between the innate and adaptive immune system there is a continuous and complicated interplay. Success in developing vaccines against "difficult" pathogens where no vaccines are currently available (HIV-1, TB and malaria) might depend on exploiting completely new methods for eliciting a protective immune response.

*Antiviral response to positive-strand RNA viruses and their replication by-products*

10

*Positive-strand RNA viruses*

Positive-strand RNA viruses encompass over one-third of all virus genera. Positive-strand RNA virus genomes are templates for both translation and replication, leading to interactions between host translation factors and RNA replication at multiple levels. All 15 known positive-strand RNA viruses carry genes for an RNA-dependent RNA polymerase (RdRp) used in genome replication. However, unlike other RNA viruses, positive-strand RNA viruses do not encapsidate this polymerase. Thus, upon infection of a new cell, viral RNA replication cannot begin until the genomic RNA is translated to produce polymerase and, for most positive-strand RNA viruses, additional replication factors. All characterized 20 positive-strand RNA viruses assemble their RNA replication complexes on intracellular membranes. In and beyond the alphavirus-like superfamily the replication of viral RNA occurs in association with spherical invaginations of intracellular membranes. For example, alphaviruses use endosomal and lysosomal membranes for their replication complex assembly. The membrane provides a surface on which replication factors are 25 localized and concentrated. This organization also helps to protect any dsRNA replication intermediates from dsRNA-induced host defence responses such as RNA interference or interferon-induced responses (Ahlquist P et al 2003).

Despite differences in genome organization, virion morphology and host range, positive-strand RNA viruses have fundamentally similar strategies for genome replication. By 30 definition, the viral (+)RNA genome has the same polarity as cellular mRNA and the viral genomic RNA is directly translated by the cellular translation machinery. Firstly, non-structural proteins are synthesized as precursor polyproteins and cleaved into mature non-structural proteins by viral proteases. A large part of the viral genome is devoted to non-structural proteins, which are not part of the virion and carry out important functions 35 during viral replication. Following translation and polyprotein processing, a complex is assembled that includes the RdRp, further accessory non-structural proteins, viral RNA and host cell factors. These so-called replication complexes (RCs) carry out viral-RNA

synthesis. Negative-sense viral RNA is synthesized early in infection and after the formation of replication complexes this negative-strand RNA is used as a template to synthesize full-length positive-sense genomic RNA as well as the subgenomic RNA. The key enzyme responsible for these steps is the RNA-dependent RNA-polymerase, which 5 act within replicase complex (Moradpour et al 2007, Miller and Krijnse-Locker 2008).

#### *Viral RNA sensing*

Positive strand RNA viruses produce in the process of replication negative strand RNA, positive strand RNA, double strand RNA (dsRNA) and subgenomic mRNA, which are 10 themselves powerful inducers of innate immune response pathways. The effect is induced through TLR3 (dsRNA), TLR7/8 (ssRNA), and some other TLRs which recognize the specific structural elements in the secondary structure of the ssRNA. For example, positive strand RNA virus, yellow fever virus live attenuated vaccine is definitely one of the most effective vaccines available that activates innate immunity via multiple Toll-like 15 receptors which also induces differential effects on the quality of the long-lasting antigen-specific T cell response (Querec TD and Pulendran B Adv Exp Med Biol. 2007;590:43-53).

As stated above, cells possess receptors and signalling pathways to induce antiviral gene 20 expression in response to cytosolic viral presence. Multiple cytokines are induced by virus infection including interleukine-6 (IL-6), IL-12 p40, and tumor necrosis factor (TNF), but the hallmark of antiviral responses is the production of type I interferons. Type I interferons include multiple subtypes encoded by separate intronless genes: one IFN- $\beta$  and 13-14 IFN- $\alpha$  subtypes, depending on species. Type I interferons can be produced by 25 all nucleated cells, including epithelial cells, fibroblasts at mucosal surfaces, and dendritic cells, in response to virus infection. In addition all cells can respond to type I interferons through the type I interferon receptor (IFNAR), which binds all subtypes.

Genes encoding the cytosolic PRRs and the components of the downstream signalling 30 pathways are themselves interferon inducible, leading to a positive-feedback loop that can greatly amplify innate antiviral responses. It has been thought that this loop is set in motion by the presence of dsRNA in cells. dsRNA fulfills the criteria for being a marker of virus infection, as long dsRNA molecules are absent from uninfected cells but can be formed by the complementary annealing of two strands of RNA produced during the 35 replication of RNA viruses. dsRNA is known to activate nuclear factor kappa B (NF- $\kappa$ B) and interferon regulatory factors-3 (IRF-3) and -7, that are essential in the synthesis of type I IFNs. Interferons mediate their antiviral response via specific cell surface receptors,

IFNAR, that activate cytoplasmic signal transducers and activators of transcription (STATs), which translocate into the nucleus and activate numerous IFN-stimulated genes (ISGs) (Rautsi et al 2007).

5 Retinoic acid-inducible gene I (RIG-I) and melanoma differentiation-associated gene 5 (MDA5) are cytoplasmic IFN-inducible DExD/H box RNA-helicases that can detect intracellular viral products, such as genomic RNA, and signal for IRF3 and IRF7 activation and for the induction of IFN- $\alpha$ , - $\beta$ , and - $\lambda$  gene expression. RIG-I is a cytosolic protein containing RNA-binding helicase domain and two caspase activation and recruitment domains (CARDs). Like RIG-I, MDA5 bears a RNA-helicase domain and two CARDs.

10 They both signal through interferon- $\beta$  promoter stimulator-1 (IPS-1). Signal adaptor IPS-1 is located on mitochondria and contains an N-terminal CARD that forms homotypic interactions with CARDs of RIG-I and Mda5. This results in activation of the C-terminal catalytic domain and the initiation of a signalling cascade that culminates in the

15 transcription of cytokine genes through activation of NF- $\kappa$ B and IRF3.

Although both RIG-I and Mda5 bind poly(I:C), a synthetic dsRNA, and signal via a common pathway, they selectively respond to different viruses. For example RIG-I detects influenza A virus, vesicular stomatitis virus (VSV), Japanese encephalitis virus (JEV), and Sendai virus (SeV), whereas MDA5 detects picornaviruses, such as encephalomyocarditis

20 virus (EMCV), Theiler's encephalomyelitis virus, and mengovirus. Independently of single or double strandedness the critical element in RIG-I stimulation by RNA is the presence of 5'-triphosphates. Which also provides explanation for the virus specificity of RIG-I.

25 Type I interferons affect various subtypes of dendritic cells (DCs). They can act as an autocrine survival factors for certain natural interferon producing cells, promote the differentiation of peripheral blood monocytes to DCs and induce their phenotypic and functional maturation. As most cell types are capable of expressing type I interferons, maturation of DCs in non-lymphoid tissues may be triggered following infection of neighbouring cells. These DCs will acquire the ability to migrate to lymphoid organs and

30 initiate T cell responses (LeBon and Tough 2002).

35 Type I interferon signalling also upregulates IFN- $\gamma$  production by DCs and T cells and thereby favours the induction and maintenance of Th1 cells. Additionally, acting directly or indirectly, they can influence the expression and function of a variety of cytokines. For example enhance interleukin-6 (IL-6) signalling, and production of anti-inflammatory transforming growth factor  $\beta$  (TGF- $\beta$ ), IL-1 receptor antagonist and soluble tumor necrosis factor (TNF) receptors. Type I interferons or their inducers can also elicit high IL-15

expression by DCs, thereby causing strong and selective stimulation of memory-phenotype CD8+ T cells (Theofilopoulos et al 2005).

Specific viral pathogen infection related patterns (like accumulation of the dsRNA in cytoplasm of the virus infected cells), recognition factors responding to these patterns (e.g. Toll-like receptors), and different anti-viral defence pathways triggered by these interactions have been described above. The complex system called innate immunity is directed to lead the cascade of events from recognition of pathogen to destroying the virus infected cells and rapid clearing of the virus infection from the body. In addition, the activation of the innate immune system is an important determinant of the quantity and quality of the adaptive immune response evoked against the viral antigens (Germain RN 2004).

*Immunological adjuvants.*

15 Immunological adjuvants were originally described by Ramon in 1924 as substances used in combination with a specific antigen that produced a more robust immune response than the antigen alone. This very broad definition includes a wide variety of materials. The immunological adjuvants available today fall broadly into two categories: delivery systems and immune potentiators (for review Fraser C.K., Diener K.R., Brown M.P. and Hayball 20 J.D. (2007) Expert Reviews in Vaccines 6(4)559-578 ).

Delivery systems can change the presentation of the antigen within the vaccine thus maximizing antigen exposure to the immune system, targeting antigen in a certain form to specific physiological locations thereby assuring pick-up of the antigen by the professional 25 Antigen Presenting Cells (APCs). Examples of immunological adjuvants presented as delivery system type adjuvants in the formulations of vaccines are alum, emulsions, saponins and cationic lipids.

30 Immune activators act directly on immune cells by activating the pathways significant for induction of adaptive immunity. These may be exogenous microbial or viral components, their synthetic derivatives or endogenous immunoactive compounds such as cytokines, chemokines and costimulatory molecules. This type of molecules can enhance specific 35 immunity to the target antigen. As of today, toll-like receptor agonists, nucleotide oligomerization domain-like receptor agonists, recombinant endogeneous compounds like cytokines, chemokines or costimulatory molecules are available and may serve as immune potentiators. It is however important to emphasize that cytokines and chemokines are species-specific molecules and therefore are not readily comparable in different

animals. In these cases the homologues of respective molecules need to be used, which considerably complicates the use of such adjuvants as well as the interpretation of experimental results in one species and the extrapolation thereof to another species.

5 DNA vaccines as several other genetic vaccines have been developed over several years and present a promising approach in the induction of specific immune responses in test animals. However, these vaccines have turned out to be ineffective in humans and larger animals. One of the reasons is probably that the reactivity and immunogenicity is lower than for traditional vaccines. A likely reason for this deficiency is the limited capacity for  
10 protein expression *in vivo*, which is of greater significance in outbred animals, including humans as well as the more homogeneous nature and lack of contaminating pathogen-derived ingredients in the actual vaccine preparation.

This has caused a need for the development of specific, finely tuned immunological  
15 adjuvants for the preparation of vaccines, which would be targeted for activation of the immune system without profound toxic effects. As a result of this need, efforts have been made to combine DNA vaccines with cytokines or chemokines, like hematopoietic growth factors, such as GM-CSF, or chemokines like MIP-1a, which can improve the immune responses against the antigen encoded by the DNA vaccine. However, unfortunately  
20 these effects are still quite weak. Co-delivery of the cytokines and chemokines as proteins requires enormous work before a good quality protein can be produced for actual use in animals or humans.

As for the use of nucleic acid based expression vectors for the expression of an adjuvant  
25 for use in combination with DNA vaccines, questions arise regarding the appropriate level and site of expression of a particular adjuvant molecule and the effect of this expression on the tissue to which the vaccine is administered.

The observations about the potential useful effect of adjuvants in immune stimulation were  
30 made in the early days by Gaston Ramon who found that higher antibody titers were developed in the horses which developed abscesses post-vaccination. The concept of using immunological adjuvants to improve antigen-specific immune responses has been inseparably linked from the early findings with their capacity to induce inflammatory processes due to contaminations. As a result, the use of such immunological adjuvants  
35 may cause clinically unacceptable toxicity and serious health concerns. Therefore, the only globally licensed adjuvant for human use is alum, a weak adjuvant capable only of inducing humoral immunity. All the other stronger adjuvants capable of inducing both

humoral and cell-mediated immunity available today are confined to experimental use only.

It has been shown that the current repertoire of vaccine adjuvants is inadequate to generate effective vaccines against significant pathogens including HIV1, malaria and tuberculosis (Riedmann et al. 2007; Fraser et al. 20007). Combination of known adjuvants may overcome

5 some of the problems associated with the vaccines that are available, however, a reliable, safe and advanced new generation of immune modulators in the form of adjuvants is certainly needed.

In view of the problems still present in the prior art explained in the above, the aim of the present invention was thus to find a more efficient adjuvant to accompany and improve the

10 responses to vaccines available today. The present invention relates to modulating the immune system, for example improving and strengthening the immune response in a subject to whom the vaccine is administered.

It is an object of the present invention to overcome or ameliorate at least one of the disadvantages of the prior art, or to provide a useful alternative.

15 **Summary of the invention**

According to a first aspect, the present invention provides use of an alphaviral replicase, said replicase comprising an RNA dependent RNA polymerase, in the manufacture of an adjuvant for modulating the immune system wherein no alphaviral template RNA containing cis-signals for interaction with the RNA dependent RNA polymerase of the replicase adjuvant is provided

20 for in said adjuvant.

According to a second aspect, the present invention provides use of an expression vector encoding an alphaviral replicase of the invention in the manufacture of an adjuvant for modulating the immune system wherein said expression vector does not express any alphaviral cis-sequences for interaction with the RNA dependent RNA polymerase of the replicase.

25 According to a third aspect, the present invention provides use of an alphaviral replicase of the invention as an adjuvant in a vaccine composition for the manufacture of a medicament for the prevention and/or treatment of an infectious disease, wherein no alphaviral template RNA containing cis-signals for interaction with the RNA dependent RNA polymerase of the replicase adjuvant is provided for in said adjuvant.

According to a fourth aspect, the present invention provides use of an alphaviral replicase or an expression vector of the invention, in the manufacture of a medicament for the prevention and/or treatment of cancer wherein no alphaviral template RNA containing cis-signals for interaction with the RNA dependent RNA polymerase of the replicase medicament is provided

5 for in said medicament.

According to a fifth aspect, the present invention provides an expression vector comprising an expression cassette, said expression cassette encoding an alphaviral replicase, which replicase essentially corresponds to SEQ ID NO:1, and wherein the replicase is mutated in the nsP2

region generating the mutant RRR>RDR in positions 1185-1187 of SEQ ID NO:1 wherein said

10 expression vector does not express any alphaviral cis-sequences for interaction with the RNA dependent RNA polymerase of the replicase.

According to a sixth aspect, the present invention provides a nucleic acid sequence essentially corresponding to SEQ ID NO:4 wherein the mutation CGG to GAC has been introduced into positions 4129-4131 of SEQ ID NO.4 wherein said nucleic acid sequence does not contain any

15 alphaviral cis-sequences for interaction with the RNA dependent RNA polymerase of the replicase.

According to a seventh aspect, the present invention provides a method of modulating the immune system said method comprising the step of administering to a subject in need thereof an alphaviral replicase as an adjuvant, said replicase comprising an RNA dependent RNA

20 polymerase wherein said method does not comprise administering viral template RNA containing cis-signals that interact with said RNA dependent RNA polymerase.

According to an eighth aspect, the present invention provides a method of modulating the immune system said method comprising the step of administering to a subject in need thereof an expression vector of the invention wherein said method does not comprise administering

25 viral template RNA containing cis-signals that interact with said RNA dependent RNA polymerase and wherein said replicase encoded by said administered expression vector is provided as an adjuvant.

According to a ninth aspect, the present invention provides a method of preventing and/or treating an infectious disease said method comprising the step of administering to a subject in

30 need thereof an alphaviral replicase or an expression vector of the invention wherein said method does not comprise administering viral template RNA containing cis-signals that interact

with said RNA dependent RNA polymerase and wherein said replicase is administered as an adjuvant.

According to a tenth aspect, the present invention provides a method of preventing and/or treating cancer said method comprising the step of administering to a subject in need thereof an

5 alphaviral replicase or an expression vector of the invention wherein said method does not comprise administering viral template RNA containing cis-signals that interact with said RNA dependent RNA polymerase and wherein said replicase is administered as an adjuvant or said replicase encoded by said administered expression vector is present as an adjuvant.

Unless the context clearly requires otherwise, throughout the description and the claims, the

10 words "comprise", "comprising", and the like are to be construed in an inclusive sense as opposed to an exclusive or exhaustive sense; that is to say, in the sense of "including, but not limited to".

The present invention relates to a novel medical use of an alphaviral replicase or of an expression vector encoding an alphaviral replicase as an immune system modulating adjuvant

15 which is species-independent, more efficient and easier to administer than the immune system modulating adjuvants available today.

The present invention is based upon the surprising discovery that the provision of an alphaviral replicase alone, comprising RNA dependent RNA polymerase (RdRp) activity and compartmentalized to the correct compartment in the cell, is able to induce innate immune

20 responses in a cell. This is possible without the presence of viral genome or any other non-structural or structural viral proteins.

Accordingly, this is a breakthrough discovery which allows for the development of efficient adjuvants which are able to activate the immune response providing a quantitatively and qualitatively more efficient response to a vaccine antigen than when a vaccine is administered

25 on its own.

Hence, in one aspect, the present invention encompasses an alphaviral replicase comprising an RNA dependent RNA polymerase (RdRp) for use as an adjuvant for modulating the immune response. Also, the present invention of course relates to the use \_\_\_\_\_

of an alphaviral replicase, said replicase comprising an RNA dependent RNA polymerase, in the manufacture of an adjuvant for modulating the immune response. In a preferred embodiment, said replicase is encoded by an expression vector, such as a DNA vector for use as an adjuvant for modulating the immune system. In one preferred embodiment, said 5 replicase is an SFV (Semliki Forest Virus) replicase.

The efficacy of the immune system modulating activity of the alphaviral replicase can be adjusted through specific mutations in the nuclear localization region of the nSP2 subunit of the replicase. Accordingly, the present invention relates to alphaviral replicases having 10 specific mutations in the nSP2 region of the wildtype replicase, for use as adjuvants for modulating the immune system and to expression vectors encoding alphaviral replicases having specific mutations in the nSP2 region of the wildtype replicase for use as adjuvants for modulating the immune system, which mutants have been shown to be even more efficient in inducing an immune response in a subject when administered together with a 15 vaccine of choice. The specific mutations shown to be efficient in the current context are RDR and AAA mutants presented in positions 1185-1187 of the wildtype SFV replicase amino acid sequence, which are further described herein.

The alphaviral replicase has been shown to be exceptionally suitable as an adjuvant by 20 being able to boost and increase the immune response in a subject to whom a vaccine, e.g. in the form of a nucleic acid based vaccine, is administered. The inventors show that the interferon response is increased *in vivo* when the adjuvant in the form of a replicase is administered together with a vaccine, as compared to when only the vaccine is administered.

25 Furthermore, the invention relates to the use of the alphaviral replicase or an expression vector encoding an alphaviral replicase as an adjuvant for modulating the immune response. The present invention also relates to use of an alphaviral replicase as disclosed herein as an adjuvant in a vaccine composition for the manufacture of a medicament for 30 the prevention and/or treatment of an infectious disease. Said vaccine accompanying the adjuvant may e.g. be in the form of a nucleic acid based vaccine or a protein-based vaccine. In addition, a method for preparing a vaccine composition comprising the adjuvant according to the invention is provided herein. The present invention also relates to a novel protein with replicase activity as well as an expression vector encoding said 35 replicase.

**Brief description of the drawings**

Figure 1. IFN-beta measured from Cop5 cell culture supernatants transfected with RdRp using different DNA concentrations. 10ng, 200ng, or 1000ng of expression vectors pRSV-Nsp1234, pRSV-RDR, pRSV-AAA, or HIV multiantigen expressing vector paraDMgB (negative control, no RdRp activity) were transfected into Cop5 cells. Cell culture supernatants were collected in three time-points (24h, 48h, and 72h) and assayed for interferon- $\beta$  expression.

Figure 2. IFN-beta measured from Cop5 cell culture supernatants transfected with RdRp using different DNA concentrations. 10ng, 200ng, or 1000ng of pRSV-RDR, pRSV-GAA, pRSV-RDR-GAA, and pRSV-AAA-GAA were transfected into Cop5 cells. Cell culture supernatants were collected in three time-points (24h, 48h, and 72h) and assayed for interferon- $\beta$  expression.

Figure nr 3. IFN-beta measured from Cop5 cell culture supernatants transfected with either transreplicase or RdRp constructs. 10ng, 200ng, or 1000ng of pRSV-SFV-Rluc, pRSV-Nsp1234, and KS123M4-RL (negative control, no RdRp activity) were transfected into Cop5 cells. Cell culture supernatants were collected in three time-points (24h, 48h, and 72h) and assayed for interferon- $\beta$  expression.

Figure 4. IFN-beta in HEK293 cells. HEK293 cells were transfected with electroporation and with the addition of carrier DNA. 1 $\mu$ g of plasmid DNA or poly(I:C) was used. Supernatants were collected at three time-points (24h, 48h, and 72h) and assayed for interferon- $\beta$  expression.

Figure 5. IFN- $\alpha$  and - $\beta$  in HACAT cells. Cells were transfected by electroporation and with the addition of carrier DNA. 1 $\mu$ g of plasmid DNA or poly(I:C) was used. Supernatants were collected at three time-points (24h, 48h, and 72h) and assayed for interferon- $\beta$  and - $\alpha$  expression. Lanes 1, 5, 9 pRSV-RDR; lanes 2, 6, 10 pRSV-RDR-GAA; lanes 3, 7, 11 poly(I:C); lanes 4, 8, 12 mock transfected.

Figure 6. IFN-gamma ELISPOT of mice. Augmentation of cellular immune response in mice when plasmid DNA is co-administrated with the plasmid pRSV-RDR at ratio 4:1 (800 ng vaccine vector and 200 ng adjuvant vector). Group 1 GTU-MultiHIV; group 2 GTU-MultiHIV+pRSV-Nsp1234; group 3 GTU-MultiHIV+pRSV-RDR; group 4 control group.

Figure 7. Augmentation of the humoral immune response against the antigens from influenza virus when the plasmid vector encoding influenza virus HA and NA is co-administrated with the DNA plasmid pRSV-RDR.

5 Figure 8. Cumulative IFN-gamma ELISPOT results against two recognized epitopes in Gag and Env, group average. Three groups of Balb/C mice were immunized two times (week 0 and week 4) with plasmid DNA encoding MultiHIV antigen alone or together with pRSV-RDR that was added either with the first or the second immunization. Fourth group was naïve. Interferon gamma Elispot was done from freshly isolated spleen cells 10 days  
10 after the second immunization. Group 1 GTU-MultiHIV; group 2 GTU-MultiHIV+pRSV-RDR with 2nd immunization; group 3 GTU-MultiHIV+pRSV-RDR with 1st immunization; group 4 naïve mice.

15 Figure 9: Cumulative Granzyme B ELISPOT results against two recognized epitopes in Gag and Env, group average. Three groups of Balb/C mice were immunized two times (week 0 and week 4) with plasmid DNA encoding MultiHIV antigen alone or together with pRSV-RDR that was added either with the first or the second immunization. Fourth group was naïve. Granzyme B Elispot was done from freshly isolated spleen cells 10 days after the second immunization. Group 1 GTU-MultiHIV; group 2 GTU-MultiHIV+pRSV-RDR with 20 2nd immunization; group 3 GTU-MultiHIV+pRSV-RDR with 1st immunization; group 4 naïve mice.

### Definitions

25 An “expression vector” refers to a DNA or RNA based vector or plasmid which carries genetic information in the form of a nucleic acid sequence. The terms “plasmid”, “vector” and/or “expression vector” may be used interchangeably herein.

30 An “RNA dependent RNA polymerase” or an “RdRp”, is an enzyme, protein or peptide having an enzymatic activity that catalyzes the *de novo* synthesis of RNA from an RNA template. A replicase is a viral polyprotein or complex of polyprotein processing products that has RdRp activity and catalyzes the replication of specific viral RNA. They are commonly encoded by viruses which have a RNA genome. Accordingly, a replicase provides the function of an RNA dependent RNA polymerase, but also further comprises additional viral non-structural polyprotein sub-units providing other functions in addition to 35 RdRp activity. A “compartmentalized” RdRp (CRdRp) is defined herein as an RdRp of a replicase that is capable of providing the RdRp activity and which is able to be directed to the correct compartment in the cell to provide its function.

The terms "antigen" and "gene of interest" as referred to herein, comprises entities, which when administered to a subject in need thereof, for example in the form of an expression vector or in the form of a peptide or a protein, directly or indirectly may generate an immune response in the subject to whom it is administered. When the antigen is a gene

5 which may provide for the expression of an antigenic protein/peptide it may also be referred to as a "gene of interest". If the gene of interest is administered in the form of an expression vector, such as a DNA vector, the immune response will be triggered when the genes encoded by the vector are expressed in the host.

10 A "vaccine" as referred to herein, is a preparation which is used to improve the immunity to a particular disease. A vaccine can comprise one or more antigen(s) derived from a pathogen which when administered to a subject in need thereof, will trigger an immune response to the one or more antigen(s), thereby inducing an immunity in the subject providing protection towards a later "real" infection with the pathogen in question.

15 Vaccines can be prophylactic, e.g. prevent or lessen the effects of a future infection by any natural pathogen, or they can be therapeutically acting when the infection is already present. In the context of the present invention, the alphaviral replicase or the expression vector encoding the alphaviral replicase is intended to be used as an adjuvant for modulating the immune response together with both a preventive and/or a therapeutic

20 vaccine. Vaccines may be dead or inactivated microorganisms or purified products derived from them. In general, there are four types of traditional vaccines. These are vaccines containing killed microorganisms which are previously virulent micro-organisms, live attenuated virus microorganisms, toxoids which are inactivated toxic compounds, or subunits of the attenuated or inactivated microorganism. A vaccine may be in the form of

25 a protein, or it may be indirect in the form of an expression vector from which one or more antigen(s) are expressed thereby inducing an immune response in a subject. In a vaccine composition as disclosed herein, any vaccine, examples of which are provided in the above, may be administered together with the adjuvant according to the invention. Hence, in the present context, a "vaccine" refers to any entity which comprises one or more

30 antigen(s) or which encodes one or more gene(s) of interest, and which when administered will generate an immune response as explained herein. A "vaccine" may also comprise additional components aiding in the administration to a subject in need thereof, such as a constituent and/or excipient, examples of which are given herein.

35 An "adjuvant" as referred to herein, may be defined as an immunological agent that can activate the innate immune system and modify the effect of other agents, such as a vaccine. An adjuvant is an agent that may stimulate the immune system and increase the

response to a vaccine, providing a stronger and more efficient immune response to the subject who is vaccinated, than when the vaccine is administered on its own. Hence, adjuvants are often used to increase or in any other manner influence the effect of a vaccine by e.g. stimulating the immune system to respond to the vaccine more vigorously.

5 thus providing increased immunity to a particular disease. Adjuvants may accomplish this task by mimicking specific sets of evolutionarily conserved molecules. Examples of such molecules are liposomes, lipopolysaccharide (LPS), bacterial cell wall components, double-stranded RNA (dsRNA), single-stranded DNA (ssDNA), and unmethylated CpG dinucleotide-containing DNA etc. The presence of an adjuvant in conjunction with the

10 vaccine can greatly increase the innate immune response to the antigen by mimicking a natural infection. When an "adjuvant" is referred to herein, what is intended is an alphaviral replicase or an expression vector encoding an alphaviral replicase with RNA dependent RNA polymerase activity as disclosed herein, providing the adjuvant function. The adjuvant may also be an expression vector, such as a DNA vector, providing for the

15 expression of an alphaviral replicase comprising the RNA dependent RNA polymerase activity. Hence, the alphaviral replicase may be administered as it is, or it may be administered in the form of an expression vector, from which the alphaviral replicase is expressed providing the adjuvant function. A vaccine composition as referred to herein, may in some embodiments comprise more than one vaccine entity, such as in the form of

20 one or more expression vector(s), encoding the one or more genes of interest, or providing the one or more antigen(s) by being e.g. a protein-based vaccine, thereby providing a cocktail of vaccines to be administered to the patient in need thereof.

By "modulating the immune system", "modulating the immune response", or an "immune system modulating activity" is meant the actions or activities which are provided by the adjuvant, as defined herein, and which effects are further explained with the term adjuvant in the above. This may for example be in the form of stimulating the immune system to respond to the vaccine more vigorously and/or providing increased immunity to a particular disease. The adjuvant according to the invention is characterized by that it when it is administered together with a vaccine will provide an increased response to the antigen being administered in the form of a vaccine, than when the vaccine is administered on its own without the adjuvant.

An "expression cassette" as disclosed herein, comprises a nucleic acid sequence encoding one or more genes or coding sequences optionally accompanied by various regulatory sequences for regulating the expression of the genes. These genes may form

part of a vaccine encoding various antigens which when expressed will generate an immune response in the host.

A "mutation" as referred to herein, constitutes a deletion, substitution, insertion and/or

5 specific point mutation that has been performed in a nucleic acid sequence to change the performance of the adjuvant function according to the invention. Specific mutations introduced into the replicase for improving the adjuvant properties thereof according to the present invention are further exemplified herein.

10 A "promoter", is a regulatory region located upstream towards the 3' region of the anti-sense strand of a gene, providing a control point for regulated gene transcription. The promoter contains specific DNA sequences, also named response elements that are recognized by transcription factors which bind to the promoter sequences recruiting RNA polymerase, the enzyme that synthesizes the RNA from the coding region of the gene.

15 In the present context, when a nucleic acid sequence or an amino acid sequence "essentially corresponds to" a certain nucleic acid or amino acid sequence, this refers to a sequence which has from 90% identity with the mentioned sequence, such as about 91, 92, 93, 94, 95, 96, 97, 99 or close to 100% identity with the present sequence. Of course,

20 in some embodiments the nucleic acid or amino acid sequence also consists of the specified sequence.

#### **Detailed description of the invention**

The present inventors disclose for the first time that an alphaviral replicase, carrying

25 functional RNA dependent RNA polymerase (RdRp) activity, is able to cause an immune system modulating effect, i.e. to act as an immune system modulating adjuvant, when administered alone without the need for any additional structural or non-structural viral proteins or genomic nucleic acid sequences to provide this effect.

30 Herein it is shown for the first time that an alphaviral replicase comprising a functional RdRp administered alone to the cells is able to induce induction of type I interferons, which activate the innate immunity and improve the quality and effectiveness of the adaptive humoral and cellular immune responses. It is envisaged that the alphaviral replicase with the functional RdRp can principally be used as immune system modulating

35 adjuvant in combination with any type of vaccine or antigen.

Furthermore, it is shown that the function of the alphaviral replicase as an immune system modulating adjuvant could be further improved by introducing specific mutations in a region of the replicase defined as the nuclear localization signal of the nSP2 subunit (Rikkonen et al. 1992).

5

It is important to note that no specific viral template RNA containing *cis*-signals for interaction with the RdRp of the replicase is needed for its activity as an immune system modulating adjuvant, which means that, without wishing to be bound by theory, the RdRp may use some cellular RNA as a template to initiate synthesis of the RNA replication intermediates in the cell cytoplasm. This is a breakthrough which provides for a novel approach for constructing an adjuvant, only rendering it necessary to administer an alphaviral replicase, e.g. in the form of a protein or encoded by an expression vector, such as a DNA vector, without any other parts of the virus, to obtain an activation of the immune response.

15

Accordingly, in a first aspect the present invention relates to an alphaviral replicase comprising an RNA dependent RNA polymerase, for use as an adjuvant for modulating the immune system. It should be understood that herein, whenever referred to an alphaviral replicase comprising an RNA dependent RNA polymerase for use as an adjuvant for modulating the immune system herein, whichever the embodiment, it also refers to use of an alphaviral replicase comprising an RNA dependent RNA polymerase for the manufacture of an adjuvant for modulating the immune response. Hence, accordingly, the present invention also in a similar aspect relates to the use of an alphaviral replicase comprising RNA dependent RNA polymerase, such as in the form of an expression vector, for the manufacture of an adjuvant for modulating the immune response.

In one preferred aspect of the invention, the alphavirus is the Semliki Forest Virus. It should be understood that herein, whenever a replicase is referred to, it always comprises the option of the replicase being a SFV replicase. In one embodiment, the amino acid sequence of the replicase of the Semliki Forest Virus essentially corresponds to SEQ ID NO:1, being suitable for use as an adjuvant for modulating the immune system. The amino acid sequence of the replicase of the Semliki Forest Virus may also consist of the sequence corresponding to SEQ ID NO:1, or of the sequences corresponding to the mutant replicases. In one preferred embodiment, said replicase is mutated in the nsP2 region generating the mutant RRR>RDR in positions 1185-1187 of SEQ ID NO:1, being suitable for use as an adjuvant for modulating the immune system. This mutated

sequence corresponds to the amino acid sequence provided in SEQ ID NO: 2, and is also encompassed by the present invention for use as an adjuvant for modulating the immune response. In another preferred embodiment, the replicase is mutated in the nsP2 region generating the mutant RRR>AAA in the positions 1185-1187 of SEQ ID NO:1, also being 5 suitable for use as an adjuvant for modulating the immune system. This mutated sequence corresponds to the amino acid sequence as provided in SEQ ID NO:3 and is also encompassed by the present invention for use as an adjuvant for modulating the immune response. The invention of course also relates to an expression vector encoding a replicase as defined in any embodiment herein, for use as an adjuvant for modulating 10 the immune response. Said replicase, either in the form of a peptide and/or a protein, and/or encoded by an expression vector, may be formulated together with a pharmaceutically acceptable excipient and/or constituent, examples of which are given herein. In yet another embodiment, a mixture of both or either of the mutated replicases as mentioned herein and/or together with the wildtype replicase, optionally expressed by 15 one or more expression vector(s) is used as an adjuvant for modulating the immune response.

It is important to note that the present inventors have for the first time discovered that an alphaviral replicase, without the presence of any additional viral antigens, can in itself act 20 as an immune system modulating adjuvant. For example, when in the form of an expression vector, the expression vector when expressed may cause an immune system modulating effect in a subject even in the absence of the simultaneous administration of additional nucleic acid sequences encoding a heterologous antigen or any other alphaviral nucleic acid sequences. To provide this effect, it has been shown that the RdRp activity of 25 the replicase is crucial as well as the ability of the replicase to proceed to the correct compartment in the cell cytoplasm, i.e. the procedure of compartmentalization of the replicase, which is further discussed in the below.

Without wishing to be bound by theory, when the adjuvant is administered in the form of 30 an expression vector, the replicase seems to be activated for expression in the cell nucleus of the transfected cells of the target tissue. It is further envisaged that upon transcription of the expression vector, the mRNA encoding the replicase is transported to the cytoplasm, where it is translated into the replicase protein that possesses cytoplasmic RNA-dependent RNA polymerase activity. This enzyme is compartmentalized to the 35 specific cytoplasmic compartments, where the RNA-dependent RNA polymerase activity generates effector molecules, including, but possibly not limited to, double-stranded RNA, inside of the cell cytoplasm, which trigger a massive, strong and long-lasting cellular

antiviral response, including the induction of expression of type I interferons. This type of induction of the antiviral response is universal, species-independent and activates both cell-mediated and humoral immune responses.

5 Accordingly, in another aspect, the present invention relates to an expression vector encoding an alphaviral replicase, such as SFV replicase, as defined herein, preferably a DNA vector, such as a plasmid DNA expression vector, which in one embodiment is pRSV-Nsp1234, corresponding essentially to the sequence as disclosed in SEQ ID NO:5, for use as an adjuvant for modulating the immune system. The nucleic acid sequence of 10 the replicase of the Semliki Forest Virus may also consist of the sequence corresponding to SEQ ID NO:5, or of the sequences corresponding to the mutant replicases. In some embodiments, the replicase encoded by the expression vector is mutated in the nsP2 region. As a general reference, the nsP2 region of an SFV replicase (SEQ ID NO:1) is located approximately in amino acid positions 538-1336 of SEQ ID NO:1. In one 15 embodiment, the expression vector encodes a replicase which is mutated in the nsP2 region generating the mutant RRR>RDR in positions 1185-1187 of SEQ ID NO:1, being suitable for use as an adjuvant for modulating the immune system. In one embodiment, said expression vector is encoded by the sequence essentially corresponding to SEQ ID NO:4, but wherein a mutation has been introduced into positions 4129-4131 of this 20 sequence, such as in one embodiment the mutation CGG to GAC, for use as an adjuvant for modulating the immune response. The nucleic acid sequence of the replicase of the Semliki Forest Virus may also consist of the sequence corresponding to SEQ ID NO:4, but wherein a mutation has been introduced into positions 4129-4131 of this sequence, such as in one embodiment the mutation CGG to GAC. In another embodiment, the expression 25 vector encodes a replicase which is mutated in the nsP2 region generating the mutant RRR>AAA in the positions 1185-1187 of SEQ ID NO:1, which is used as an adjuvant for modulating the immune system. In one embodiment, the expression vector is encoded by the sequence essentially corresponding to SEQ ID NO:4, but wherein a mutation has been introduced in positions 4126-4133 of this sequence, such as in one embodiment the 30 mutation CGGCGGAG to GCCGCCGC, for use as an adjuvant for modulating the immune response. The nucleic acid sequence of the replicase of the SFV may also consist of the sequence corresponding to SEQ ID NO:4, but wherein a mutation has been introduced in positions 4126-4133 of this sequence, such as in one embodiment the mutation CGGCGGAG to GCCGCCGC. This means that in the respective amino acid 35 sequences, the wild type amino acid sequence has been altered from RRR to RDR and AAA, respectively, in positions 1185-1187 in SEQ ID NO:1. Said expression vector, mutated or not, may in a preferred embodiment be a DNA vector. Said vector may also be

a viral expression vector, such as an adenoviral vector or a herpesvirus-based vector or any other usable viral expression vector. In one embodiment, the expression vector is a RNA-based vector. In yet another embodiment, the adjuvant is administered in the form of alphaviral replicase mRNA. In one embodiment, the invention relates to an alphaviral replicase plasmid DNA expression vector which is pRSV-AAA, essentially corresponding to the nucleic acid sequence disclosed in SEQ ID NO:5, wherein positions 5126-5133 have been mutated from CGGCGGAG to GCCGCCGC, for use as an adjuvant for modulating the immune system. In another embodiment, the invention relates to an alphaviral plasmid DNA expression vector which is pRSV-RDR, essentially corresponding to SEQ ID NO:5, wherein positions 5129-5131 have been mutated from CGG to GAC, for use as an adjuvant for modulating the immune system. The nucleic acid sequence of the replicase of the Semliki Forest Virus may also consist of the sequence corresponding to SEQ ID NO:5, or of the sequences corresponding to the mutant replicases mentioned in the above.

As is understood by the skilled person, an expression vector according to the invention encoding the replicase for use as an adjuvant for modulating the immune system may of course also comprise additional commonly used components aiding in the expression of the vector, such as various regulatory sequences in the form of promoters, enhancers, etc. The expression vector encoding a replicase as defined herein for use as an adjuvant for modulating the immune system may also comprise an origin of replication and/or a selection marker, such as an antibiotic selection marker or a selection system based upon the *araD* gene, as provided for in the applicants own application published as WO2005/026364. Such a selection system as disclosed in WO2005/026364 comprises a bacterial cell deficient of an *araD* gene into which a vector carrying an *araD* gene, preferably a bacterial *araD* gene, such as an *araD* gene from *E.coli*, a complementary sequence thereof, or a catalytically active fragment thereof has been added as a selection marker. The *araD* gene encodes a functional L-ribulose-5-phosphate 4-epimerase (EC 5.1. 3.4.).

As demonstrated in the experimental section, the expression of the mutated forms of the replicase, also acts as immune system modulating adjuvants. Moreover, the mutations can modulate the adjuvant activity of the replicase: the RDR mutant has enhanced ability of type I IFN induction compared to (wildtype) wt replicase expression (Example 2). The replicase with the RRR>AAA mutation acts as an immune system modulating adjuvant similarly to the wildtype replicase (Example 2). It is also demonstrated in the experimental

section that transfection of the different human and mouse cells with replicase-based expression vectors alone induced activation of type I interferon production (Example 2)

The results described in the experimental section clearly demonstrate that the RNA-dependent RNA polymerase (RdRp) activity of the replicase is absolutely necessary for immune modulation activity. The signature GDD motif of viral RNA polymerases is located in the region of nsp4 of the alphaviral replicase wherein the RdRp enzymatic activity is located. The mutation GDD>GAA in this motif destroys the RdRp activity (Tomar et al. 2006). Introduction of the GDD>GAA mutation into the replicase completely abolishes the induction of the Type I interferon response (Example 2), thereby demonstrating the necessity of the RdRp activity for the immune system modulating effect.

Experimental data also showed that the expression of replicases with a functional RdRp activity but not the replicases with the GDD>GAA mutation resulted in the accumulation of dsRNA in the cytoplasm of the transfected cells. Without wishing to be bound by theory, these results indicate that the immune system modulating activity of the replicase may at least partially be mediated by the dsRNA recognition pathway, wherein the replicase produces dsRNA from endogenous RNA in the cytoplasm. However, it is not excluded that other pathways (e.g. via recognition of uncapped RNA) are involved. In some cases, induction of the type I IFN response was observed without indication of dsRNA accumulation in cytoplasm (Example 3).

In addition, different kinetic patterns were observed when the IFN response was induced by the SFV replicase expression compared to induction by synthetic dsRNA (poly I:C) transfection. In the experiments with the replicase expression vector transfections, the IFN level was increased during the first days after transfection. In contrast, the IFN level showed the maximum value in the first time point (24h) after transfection with synthetic dsRNA, and decreased thereafter (Example 2).

Immunological data presented in the experimental section clearly demonstrate that co-administration of the MultiHIV antigen DNA vaccine (Blazevic et al. 2006) together with the expression vector encoding the replicase, in this case the SFV replicase, significantly enhance quantitatively the cell-mediated immune response if compared with immunization with the DNA vaccine alone (measured by the ELISPOT assays) (Figure 6). In addition, the values were clearly higher in the case with the replicase with the RRR>RDR mutation than the wildtype replicase (Example 4). Thus, the immunological data correlates with the results of IFN response induction: no positive effect to cell mediated immunity was

observed if the replicase with destroyed RdRp activity (GDD>GAA) mutation was co-administered with the DNA vaccine. This clearly shows the importance of the RdRp activity for providing the adjuvant effect according to the invention.

5 The triggering of innate immunity responses, like type I IFN response by SFV infection, is well known in the art. It has also been shown that the immune modulation activity of the alphaviruses can be tuned by introducing mutations in the nsP2 region of the non-structural polypeptide of the replicase. The infection of primary mouse fibroblasts with SFV (Semliki Forest Virus) that had single point mutation RRR>RDR in nsP2 NLS, 10 resulted in increased expression of type I IFN and the proinflammatory cytokine TNF- $\alpha$  in virus infected cells, if compared to wt SFV infection (Breakwell et al. 2007). It should however be pointed out that in Breakwell et al. the cells were infected with whole virus particles resulting in delivery, expression and replication of the whole viral genome, and, thereby generating the IFN response.

15 However, differently from prior art, the present invention have demonstrated that the induction of IFN response is not bound to viral infection and viral genome replication itself, but also can be obtained by the expression of the viral non-structural polyprotein, i.e. the replicase, alone without including the viral genome, viral particles or structural proteins.

20 Moreover, it is demonstrated that the SFV replicase can be expressed from codon-optimised cDNA that have low homology with natural nucleic acids of SFV and still provide the adjuvant effect. An example of such a codon-optimized sequence is provided in SEQ ID NO:4. When expressed, SEQ ID NO:4 provides for the amino acid sequence as disclosed in SEQ ID NO:1.

25 It is to be understood that nucleic acid and amino acid sequences as referred to herein forming part of the present invention also comprise nucleic acid and amino acid sequences with approximately 90% identity to these sequences, such as 90, 91, 92, 93, 94, 95, 96, 97, 98, or 99 % identity with the sequences. This means that the sequences 30 may be shorter or longer or have the same length as the sequences disclosed herein, but wherein some positions in the nucleic acid sequence or the amino acid sequence have been altered in a suitable manner. However, when a mutated alphaviral replicase is used, the mutated sequence will always be present and hence be excluded when determining the identity of a sequence with the specific sequence disclosed herein. The sequence 35 used in the present invention may hence be altered in any suitable manner for the intended purpose, such as by the introduction, change and/or removal of a specific nucleic acid in the nucleic acid sequence, or an amino acid in the amino acid sequence. It is

important to note that even if the sequence is altered, the RNA dependent RNA polymerase activity of the replicase expressed from the expression vector remains.

In some embodiments of the present invention, said adjuvant as defined herein, for use as  
5 an adjuvant for modulating the immune system, is formulated together with a pharmaceutically acceptable excipient and/or constituent. Such a pharmaceutically acceptable excipient and/or constituent may be chosen from any suitable source. Examples of pharmaceutical excipients are liquids, such as water or an oil, including those of petroleum, animal, vegetable, or synthetic origin, such as peanut oil, soybean oil, mineral oil, sesame oil and the like. The pharmaceutical excipients can be saline, gum acacia, gelatin, starch paste, talc, keratin, colloidal silica, urea and the like. In addition, auxiliary, stabilizing, thickening, lubricating, and coloring agents can be used. In one embodiment, the pharmaceutically acceptable excipients are sterile when administered to an animal. Saline solutions and aqueous dextrose and glycerol solutions can also be  
10 employed as liquid excipients, particularly for injectable solutions. Suitable pharmaceutical excipients also include starch, glucose, lactose, sucrose, gelatin, malt, rice, flour, chalk, silica gel, sodium stearate, glycerol monostearate, talc, sodium chloride, dried skim milk, glycerol, propylene, glycol, water, ethanol and the like. A composition with the adjuvant can, if desired, also contain minor amounts of wetting or emulsifying agents, or pH  
15 buffering agents. The present compositions can also take the form of solutions, suspensions, emulsion, tablets, pills, pellets, capsules, capsules containing liquids, powders, sustained-release formulations, suppositories, emulsions, aerosols, sprays, suspensions, or any other form suitable for use. In one embodiment, the composition is in the form of a capsule. Other examples of suitable pharmaceutical excipients are described in  
20 25 Remington's Pharmaceutical Sciences 1447-1 676 (Alfonso R. Gennaro ed., 19th ed. 1995). In one embodiment, the adjuvant according to the invention is formulated in accordance with routine procedures as a composition adapted for oral administration to human beings. Compositions for oral delivery can be in the form of tablets, lozenges, aqueous or oily suspensions, granules, powders, emulsions, capsules, syrups, or elixirs,  
30 for example. Oral compositions can include standard excipients such as mannitol, lactose, starch, magnesium stearate, sodium saccharin, cellulose, and magnesium carbonate. In one embodiment, the excipients are of pharmaceutical grade. In another preferred embodiment, the adjuvant can be formulated for intravenous administration. Typically, compositions for intravenous administration comprise sterile isotonic aqueous buffer.  
35 Where necessary, the compositions can also include a solubilizing agent.

Methods of administration of the expression vector according to the invention comprise, but are not limited to, intradermal, intramuscular, intraperitoneal, intravenous, subcutaneous, intranasal, epidural, oral, sublingual, intracerebral, intravaginal, transdermal, rectal, by inhalation, or topical, particularly to the ears, nose, eyes, or skin.

5 The mode of administration can be left to the discretion of the practitioner. In an especially preferred embodiment, the adjuvant according to the invention, optionally in combination with a suitable vaccine, is administered to a patient in need thereof by a Gen Gun methodology ( Klein et al 1992), by injections combined with electroporation ("electroporation-mediated DNA drug delivery"; intradermal or intramuscular), by topical 10 administration onto mucosal surfaces (e.g. in the form of intranasal spray). The genetic adjuvant can be also combined with specific delivery adjuvants, which facilitate uptake of plasmid DNA by cells (e.g. polyethylenimide and other similar).

Electroporation (EP) utilizes the in vivo application of electrical fields to enhance the 15 intracellular delivery of agents of interest in a targeted region of tissue. The EP delivery technique is dependent on the propagation of threshold level electrical fields throughout the target tissue site after the agent of interest has been distributed within the interstitial space of said tissue. This spatial and temporal "co-localization" of electrical fields and therapeutic agent in the target tissue is a critical requirement for achieving efficacious 20 DNA delivery.

Electroporation has been demonstrated to be effective on both prokaryotic and eukaryotic cells and is capable of introducing DNA, large macromolecules (e.g., antibodies), proteins, dyes, metabolic precursors (e.g., 32P-ATP), and nonpermeant drugs and metabolites into 25 cells with high efficiency. (De Lise et al, Developmental Biology Protocols; Jan 21;2000).

In one aspect of the present invention, the adjuvant may optionally be administered together with the vaccine of choice in a vaccine composition as a first immunization to the patient in need thereof. Some results provided by the present inventors have shown that 30 such a mode of administration of the adjuvant may provide an improved immune response as compared to when the adjuvant is administered together with the vaccine in the second round of immunization (see Figure 8 and 9). Hence, in one aspect, the present invention relates to a method of administering a vaccine composition as defined herein, said vaccine composition comprising an adjuvant as defined herein, wherein said adjuvant is 35 administered as part of the vaccine composition in the first immunization of the patient in need of said treatment. Optionally the co-administration of the adjuvant with the vaccine in a vaccine composition is only performed with the first immunization dose, i.e. no adjuvant

is administered if additional doses of the vaccine are administered at a later stage to the individual in need thereof.

Hence, yet another aspect of the present invention relates to an alphaviral replicase, said 5 replicase comprising an RNA dependent RNA polymerase, for use in a vaccine composition to be administered as a first immunization dose. Accordingly, in one aspect the present invention relates to a method of administering an adjuvant in a vaccine composition as defined herein, said adjuvant comprising an alphaviral replicase, said replicase comprising an RNA dependent RNA polymerase, wherein said administration of 10 the adjuvant is performed with the first immunization dose of the vaccine composition to a patient in need thereof. In the present context, the "first immunization dose" refers to when the vaccine comprising one or more antigen(s) is administered to the patient in need thereof for the first time, thereafter triggering an immune response to the vaccine (i.e. the one or more antigen(s) administered therewith). In another aspect, the present invention 15 relates to the use of an alphaviral replicase, said replicase comprising an RNA dependent RNA polymerase in the manufacture of a vaccine composition wherein said adjuvant is to be administered with the first immunization dose.

It should however be noted that the present invention is not limited to the mode of 20 administration mentioned in the above, i.e. to be administered (optionally only) with the first immunization dose, and it may also well be so that the skilled practitioner will find additional alternative methods of administration which will function in a similar and equally preferred manner.

25 In another aspect, the invention relates to the use of an alphaviral replicase, or an expression vector encoding an alphaviral replicase, said replicase comprising an RNA dependent RNA polymerase, as an adjuvant for modulating the immune system. In one embodiment, said alpha virus is the Semliki Forest Virus. In yet another embodiment, said replicase used as an adjuvant for modulating the immune system corresponds to the 30 amino acid sequence essentially as disclosed in SEQ ID NO:1. The amino acid sequence of the replicase of the Semliki Forest Virus may also consist of the sequence corresponding to SEQ ID NO:1, or of the sequences corresponding to the mutant replicases. In another preferred embodiment, the invention relates to the use of an alphaviral replicase, said replicase comprising an RNA dependent RNA polymerase, as 35 an adjuvant for modulating the immune system, wherein the replicase is mutated in the nsP2 region generating the mutant RRR>RDR in positions 1185-1187 of SEQ ID NO:1, represented by SEQ ID NO:2. In another preferred embodiment, the replicase is mutated

in the nsP2 region generating the mutant RRR>AAA in the positions 1185-1187 of SEQ ID NO:1, represented by SEQ ID NO:2. In some embodiments, the replicase as such defined is encoded by an expression vector, which in some embodiments is a DNA vector. Optionally, said replicase may be formulated together with a pharmaceutically acceptable 5 excipient and/or constituent.

As demonstrated in example 5, the replicase with the mutation RRR>RDR also enhance the quantity of antibody response evoked by immunisation with DNA vaccine expressing the influenza antigens. The experimental data shows that the antibody levels were highest 10 in the cases when the SFV replicase unit is co-administrated with influenza DNA vaccine, giving even higher values than well-defined adjuvant GM-CSF expression vector when co-administrated with the vaccine vector.

In yet another preferred aspect, the invention relates to the use of an alphaviral replicase, 15 being either wildtype, codon-optimized or mutated, such as with an RDR or an AAA mutation as further defined herein, or an expression vector, such as a DNA vector, encoding an alphaviral replicase as defined herein, said replicase comprising an RNA dependent RNA polymerase, as an adjuvant for modulating the immune response when present in a vaccine composition, for the manufacture of a medicament for the prevention 20 and/or treatment of an infectious disease. The present invention also relates to the use of an alphaviral replicase, as defined herein, as an adjuvant, in the manufacture of a vaccine composition. Said vaccine composition is preferably used for the prevention and/or treatment of an infectious disease. The present invention also relates to an alphaviral replicase, as defined herein being either wildtype, codon-optimized or mutated, such as 25 with an RDR or an AAA mutation as further defined herein, or an expression vector encoding an alphaviral replicase, said replicase comprising an RNA dependent RNA polymerase, for use as an adjuvant for modulating the immune response when present in a vaccine composition, for the prevention and/or treatment of an infectious disease. As previously stated herein, the replicase may essentially correspond to the amino acid 30 sequences as disclosed in SEQ ID NO:1, 2 or 3. Furthermore, the replicase may consist of the sequences as disclosed in SEQ ID NO:1, 2 or 3. In one embodiment, the vaccine composition, wherein the alphaviral replicase is present as an adjuvant, optionally encoded by an expression vector, is used for the prevention and/or treatment of an infectious disease. In one embodiment, the vaccine composition wherein the alphaviral 35 replicase, optionally encoded by an expression vector, is present as an adjuvant is used for the prevention and/or treatment of a bacterial disease. In another embodiment, the vaccine composition wherein the alphaviral replicase, optionally encoded by an

expression vector, is present as an adjuvant is used for the prevention and/or treatment of a viral disease, which viral disease preferably is caused by HIV (Human Immunodeficiency Virus; HIV-I, HIV-II), potentially leading to AIDS. In yet another embodiment, the vaccine composition wherein the alphaviral replicase is present,

5     optionally encoded by an expression vector, as an adjuvant is used for the prevention and/or treatment of cancer. The vaccine which is administered in combination with the replicase providing the adjuvant properties of the composition may be any suitable vaccine for the present purpose. In some embodiments, the vaccine is protein-based, and in other embodiments the vaccine is an expression vector which encodes one or more

10    antigen(s) or gene(s) of interest. The expression vector may be any suitable nucleic acid based expression vector encoding one or more genes of interest or antigens capable of inducing a specific immune response in a host to which the vaccine composition is administered. In one preferred embodiment, the vector of the vaccine composition is based upon an influenza virus.

15    Accordingly, in one aspect, the present invention relates to a vaccine composition comprising an alphaviral replicase as defined in any of the embodiments herein providing an adjuvant effect, and a vaccine of choice, also as defined herein. The vaccine may optionally be GTU-MultiHIV. (Blazevic V, et al. AIDS Res Hum Retroviruses. 2006

20    Jul;22(7):667-77.). Accordingly, the vaccine in the vaccine composition may in some aspects contain one or more structural or non-structural HIV protein(s) of choice, such as the antigens which are disclosed in the applicant's own publication WO02090558.

25    The replicase adjuvant and the antigen may in the context of the present invention be encoded by the same expression vector, wherein the replicase provides the adjuvant properties and the vaccine part of the vector is a separate independent part of the vector providing its function independently of the replicase. Despite thereof, the replicase may optionally be fused to any other coding sequence in any expression vector encoding an antigen. The expression vector encoding the adjuvant and/or the vaccine may in some

30    embodiments be a DNA vector. As will be understood by the skilled person, the vaccine composition according to the invention may also comprise more than one vaccine unit, meaning that a cocktail of several vaccines may be administered to a subject in need thereof together with the adjuvant according to the invention.

35    In yet another aspect, the present invention relates to the use of an alphaviral replicase as defined herein in a vaccine composition as an adjuvant for modulating the immune response for the manufacture of a medicament for the prevention and/or treatment of an

infectious disease or the use of an alphaviral replicase as defined herein as an adjuvant for the manufacture of a vaccine composition, wherein the vaccine comprising the one or more gene(s) of interest is an expression vector comprising:

- a. a DNA sequence encoding a nuclear-anchoring protein operatively linked to a heterologous promoter, said nuclear-anchoring protein comprising
  - (i) a DNA binding domain which binds to a specific DNA sequence, and
  - (ii) a functional domain that binds to a nuclear component, or a functional equivalent thereof; and
- b. a multimerized DNA binding sequence for the nuclear anchoring protein, wherein said vector lacks an origin of replication functional in mammalian cells.

Said vaccine composition as defined herein may be used in the treatment and/or prevention of an infectious disease, such as HIV infection, as well as in the treatment of a bacterial disease or cancer.

The present invention also relates to an alphaviral replicase as defined herein for use as an adjuvant for modulating the immune response in a vaccine composition for the prevention and/or treatment of an infectious disease, wherein the vaccine comprising the one or more gene(s) of interest is an expression vector comprising:

- a) a DNA sequence encoding a nuclear-anchoring protein operatively linked to a heterologous promoter, said nuclear-anchoring protein comprising
  - (i) a DNA binding domain which binds to a specific DNA sequence, and
  - (ii) a functional domain that binds to a nuclear component, or a functional equivalent thereof; and
- b) a multimerized DNA binding sequence for the nuclear anchoring protein, wherein said vector lacks an origin of replication functional in mammalian cells.

The term "nuclear-anchoring protein" refers to a protein, which binds to a specific DNA sequence and which is capable of providing a nuclear compartmentalization function to the vector, i. e., to a protein, which is capable of anchoring or attaching the vector to a specific nuclear compartment. In one embodiment, said nuclear-anchoring protein is the E2 protein from the Bovine Papilloma Virus Type 1. In another preferred embodiment, part i) and/or part ii), i.e. the DNA binding domain binding to a specific DNA sequence and/or the functional domain which binds to a nuclear component, is obtained from the E2 protein of the Bovine Papilloma Virus type 1. In one embodiment, said protein is a recombinant and/or a synthetic protein. A nuclear component may for example be mitotic chromatin, the nuclear matrix, nuclear domain 10 (ND10), or nuclear domain POD.

Such vectors which may form part of the vaccine compositions for use together with the replicase adjuvant according to the invention are further disclosed in applicants own application published as WO02090558, as well as in (Blazevic V, et al. AIDS Res Hum 5 Retroviruses. 2006 Jul;22(7):667-77.) . It should be noted that these vectors are however only examples of vectors that may be combined with the replicase for use as an adjuvant according to the present invention forming a vaccine composition as disclosed herein. Any suitable expression vector functioning as a vaccine may be formulated together with the replicase for use as an adjuvant therein according to the invention to produce a 10 composition which will generate a stronger and more efficient immune response in the subject to which the vector is administered, than the administration of a vaccine alone. In one embodiment, the present invention relates to the use of an alphaviral replicase said replicase comprising an RNA dependent RNA polymerase for use as an adjuvant for modulating the immune system in a vaccine composition for the manufacture of a 15 medicament for the prevention and/or treatment of an infectious disease.

Regarding vaccine compositions, wherein the replicase is used as an adjuvant, it should be noted that is it up to the skilled practitioner to determine the suitable dosage and the amounts of the adjuvant and/or the vaccine present in the vaccine composition for the 20 subject in need of a treatment with the adjuvant as disclosed herein. In one preferred aspect, the replicase which is part of the vaccine composition is encoded by an expression vector, which preferably is a DNA vector. Said vaccine may also in some embodiments be an expression vector, such as a DNA vector, or it may be a protein-based vaccine.

25 In another aspect, the present invention relates to a method for preparing a vaccine composition as disclosed herein comprising therein an alphaviral replicase for use as an adjuvant, comprising mixing a suitable amount of the alphaviral replicase or an expression vector encoding an alphaviral replicase comprising a RNA dependent RNA polymerase 30 with a suitable amount of the vaccine and optionally adding a pharmaceutically acceptable excipient and/or constituent. The suitable amounts of the respective ingredients may be determined by the skilled practitioner; however examples of some preferred doses are also given herein.

35 In yet another aspect, the present invention relates to a method comprising administering a suitable amount of a vaccine composition comprising therein an alphaviral replicase or an expression vector encoding an alphaviral replicase for use as an adjuvant according to

the present invention to a subject in need thereof. The administration route for the vaccine composition may be any suitable route as determined by the skilled practitioner, examples of which are given herein. A subject in need thereof may be any mammal, such as a human being or an animal.

5

In yet another aspect, the invention relates to a method for administering an alphaviral replicase comprising RNA dependent RNA polymerase, optionally encoded by an expression vector, as an adjuvant for modulating the immune response to a subject in need thereof, said adjuvant being administered in combination with a vaccine in a suitable amount, when administered providing an increase in the immune response in the subject to whom the adjuvant and the vaccine is administered as compared to when the vaccine is administered on its own.

10 In yet another aspect, the invention relates to a protein essentially corresponding to the amino acid sequence disclosed in SEQ ID NO:3. The protein may also consist of the amino acid sequence as disclosed in SEQ ID NO:3. In yet another aspect, the invention relates to a protein essentially corresponding to SEQ ID NO:1, but wherein a mutation generating the change in amino acids from RRR to AAA has been performed in positions 1185-1187 of SEQ ID NO:1. The protein may also consist of the sequence corresponding 15 to SEQ ID NO:1, but wherein a mutation generating the change in amino acids from RRR to AAA has been performed in positions 1185-1187 of SEQ ID NO:1. In yet another aspect, the invention relates to a protein essentially corresponding to the amino acid sequence as disclosed in SEQ ID NO:3, for use as a medicament. In yet another aspect, the invention relates to a protein consisting of the amino acid sequence as disclosed in 20 SEQ ID NO:3, for use as a medicament. In yet another aspect, the present invention relates to a protein essentially corresponding to the amino acid sequence as disclosed in SEQ ID NO:3, for use as an adjuvant for modulating the immune response. In yet another aspect, the present invention relates to the use of a protein essentially corresponding to the amino acid sequence as disclosed in SEQ ID NO:3, for the manufacture of an 25 adjuvant for modulating the immune response. In yet another aspect, the invention relates to a protein encoded by a nucleic acid sequence essentially corresponding to the sequence as disclosed in SEQ ID NO:4, but wherein a mutation has been introduced into positions 4126-4133 changing CGGCGGGAG to GCCGCCGC. In yet another aspect, the invention relates to a protein encoded by a nucleic acid sequence consisting of the 30 sequence as disclosed in SEQ ID NO:4, but wherein a mutation has been introduced into positions 4126-4133 changing CGGCGGGAG to GCCGCCGC. In yet another aspect, the invention also relates to a nucleic acid sequence essentially corresponding to the

sequence as disclosed in SEQ ID NO:4, but wherein a mutation has been introduced into positions 4126-4133 changing CGGCAG to GCCGCCGC. Furthermore, the invention also relates to a nucleic acid sequence consisting of the sequence as disclosed in SEQ ID NO:4, but wherein a mutation has been introduced into positions 4126-4133 changing 5 CGGCAG to GCCGCCGC.

In yet another aspect, the invention relates to an expression vector comprising an expression cassette comprising a sequence essentially corresponding to the sequence as disclosed in SEQ ID NO:4, but wherein a mutation has been introduced into positions 10 4126-4133 of SEQ ID NO:4, generating when expressed the mutant RRR>AAA in positions 1185-1187 of SEQ ID NO:1 (SEQ ID NO:3). In yet another aspect, the invention relates to an expression vector comprising an expression cassette consisting of a sequence essentially corresponding to the sequence as disclosed in SEQ ID NO:4, but wherein a mutation has been introduced into positions 4126-4133 of SEQ ID NO:4, 15 generating when expressed the mutant RRR>AAA in positions 1185-1187 of SEQ ID NO:1 (SEQ ID NO:3). In yet another aspect, the invention relates to an expression vector comprising an expression cassette comprising a sequence essentially corresponding to the sequence as disclosed in SEQ ID NO:4, wherein a mutation has been introduced into positions 4126-4133 of SEQ ID NO:4, generating when expressed the mutant RRR>AAA 20 in positions 1185-1187 of SEQ ID NO:1, generating when mutated the amino acid sequence as disclosed in SEQ ID NO:3, for use as a medicament.

In yet another aspect, the present invention relates to the use of an alphaviral replicase, said replicase comprising an RNA dependent RNA polymerase, for the manufacture of an 25 adjuvant for modulating the immune system. Said alpha virus may optionally be the Semliki Forest Virus. In some aspects, the amino acid sequence of the replicase essentially corresponds to SEQ ID NO:1. The amino acid sequence of the replicase may also consist of the sequence corresponding to SEQ ID NO:1, or of the mutated versions of the replicase mentioned herein. In other aspects, the replicase is mutated in the nsP2 30 region generating the mutant RRR>RDR in positions 1185-1187 of SEQ ID NO:1. In yet another aspect, the replicase is mutated in the nsP2 region generating the mutant RRR>AAA in the positions 1185-1187 of SEQ ID NO:1.

The present invention also relates to the use of an expression vector encoding an 35 alphaviral replicase as defined herein, for the manufacture of an adjuvant for modulating the immune system. In some aspects, said expression vector is a DNA vector. Said

replicase or said expression vector encoding said replicase may also be formulated together with a pharmaceutically acceptable excipient and/or constituent.

## EXPERIMENTAL SECTION

### Expression Vectors

5 pRSV-Nsp1234 (SEQ ID NO:5) is a 10342 bp plasmid vector which expresses codon optimised SFV replicase (SEQ ID NO:4) from an RSV LTR promoter. Heterologous rabbit beta-globin gene derived intron is introduced into the replicase coding sequence.

Main features:

	Start-End	Description
10	9933-268	pUCori
	437-963	RSV LTR
	1001-8869	SFV replicase coding sequence with intron (SEQ ID NO:4)
	1213-1785	intron
	8878-9090	bgh pA
15	9204-9899	araD selection marker

pRSV-AAA is identical to pRSV-Nsp1234 (SEQ ID NO:5) but contains the RRR to AAA mutation in the aa 1185-1187 of SEQ ID NO:1: the nucleotide sequence in positions 5126-5133 is mutated from CGGCGGAG to GCCGCCGC.

20 pRSV-RDR is identical to pRSV-Nsp1234 (SEQ ID NO:5) but contains the RRR to RDR mutation in the aa 1185-1187 of SEQ ID NO:1: the nucleotide sequence in positions 5129-5131 is mutated from CGG to GAC.

25 pRSV- GAA is identical to pRSV-Nsp1234 (SEQ ID NO:5) but contains the GDD to GAA mutation in the aa 2283-2285 of SEQ ID NO:1: the nucleotide sequence in positions 8424-8427 is mutated from ACGA to CCGC.

30 pRSV- AAA-GAA is identical to pRSV-Nsp1234 (SEQ ID NO:5) but contains the RRR to AAA mutation in the aa 1185-1187 of SEQ ID NO:1: the nucleotide sequence in positions 5126-5133 is mutated CGGCGGAG to GCCGCCGC; and GDD to GAA mutation in the aa 2283-2285 of Nsp1234 : the nucleotide sequence in positions 8424-8427 is mutated from ACGA to CCGC.

35 pRSV- RDR-GAA is identical to pRSV-Nsp1234 (SEQ ID NO:5) but contains the RRR to RDR mutation in the aa 1185-1187 of SEQ ID NO:1: the nucleotide sequence in positions 5129-5131 is mutated from CGG to GAC; and GDD to GAA mutation in the aa 2283-2285

of Nsp1234 : the nucleotide sequence in positions 8424-8427 is mutated from ACGA to CCGC.

phEF4A1-Nsp1234 (SEQ ID NO:6) is a 10248 bp plasmid vector which expresses codon 5 optimised SFV replicase (SEQ ID NO:4) from human eIF4A1 promoter. Heterologous rabbit beta-globin gene derived intron is introduced into the replicase coding sequence.

Main features:

	Start-End	Description
	9839-268	pUCori
10	367-894	hEF4A1 promoter
	907-8775	SFV replicase coding sequence with intron (SEQ ID NO:4)
	1119-1691	intron
	8784-8996	bgh pA
	9110-9805	araD selection marker

15

phEF4A1- AAA is identical to phEF4A1-Nsp1234 (SEQ ID NO:6) but contains the RRR to AAA mutation in the aa 1185-1187 of SEQ ID NO:1: the nucleotide sequence in positions 5032-5039 is mutated from CGGCAG to GCCGCCGC.

20 phEF4A1- RDR is identical to phEF4A1-Nsp1234 (SEQ ID NO:6) but contains the RRR to RDR mutation in the aa 1185-1187 of SEQ ID NO:1: the nucleotide sequence in positions 5035-5037 is mutated from CGG to GAC.

25 phEF1aHTLV-Nsp1234 (SEQ ID NO:7) is 10258 bp plasmid vector expresses codon optimised SFV replicase (SEQ ID NO:4) from human EF1a promoter plus HTLV UTR. Heterologous rabbit beta-globin gene derived intron is introduced into the replicase coding sequence.

Main features:

	Start-End	Description
30	9849-268	pUCori
	372-903	hEF1a/HTLV
	917-8785	SFV replicase coding sequence with intron (SEQ ID NO:4)
	1129-1701	intron
	8794-9006	bgh pA
35	9120 9815	araD selection marker

phEF1aHTLV- AAA is identical to phEF1aHTLV-Nsp1234 (SEQ ID NO:7) but contains the RRR to AAA mutation in the aa 1185-1187 of SEQ ID NO:1: the nucleotide sequence in positions 5042-5049 is mutated from CGGCGGAG to GCCGCCGC.

5 phEF1aHTLV- RDR is identical to phEF1aHTLV-Nsp1234 (SEQ ID NO:7) but contains the RRR to RDR mutation in the aa 1185-1187 of SEQ ID NO:1: the nucleotide sequence in positions 5045-5047 is mutated from CGG to GAC.

10 phEF1aHTLV- GAA is identical to phEF1aHTLV-Nsp1234 (SEQ ID NO:7) but contains the GDD to GAA mutation in the aa 2283-2285 of SEQ ID NO:1: the nucleotide sequence in positions 8340-8343 is mutated from ACGA to CCGC.

**Example 1. Construction of the DNA plasmids expressing the SFV replicase with mutation RRR>RDR in nsP2 region.**

15 Previously, the SFV replicase protein sequence (non-structural polypeptide nsP1234) (SEQ ID NO: 1) was back-translated and codon-optimised synthetic cDNA with heterologous rabbit beta-globin gene derived intron (introduced into the coding sequence) was synthesised (SEQ ID NO: 4). The cDNA was inserted into the expression plasmids so 20 that different heterologous Pol II promoter and UTR elements were used for expression of SFV replicase from the codon-optimised coding sequence (figure 5). Particularly, Rous sarcoma virus 5'LTR, human eIF4A1 promoter and chimeric promoter consisting of human EF1a promoter plus HTLV UTR were utilised. The vectors expressing SFV replicase (SEQ ID NO:1) were named pRSV-Nsp1234 (SEQ ID NO 5), phelF4A1-Nsp1234 (SEQ ID NO 6), and phEF1aHTLV-Nsp1234 (SEQ ID NO 7). In addition, mutations in amino acids 25 1185-1187 RRR>AAA, in the nsP2 NLS region, were introduced into the vectors pRSV-Nsp1234, phelF4A1-Nsp1234, and phEF1aHTLV-Nsp1234. The plasmids were named pRSV-AAA, phelF4A1-AAA, and phEF1aHTLV-AAA, respectively.

30 It is known by literature data that a particular mutation in aa 1185-1187, RRR>RDR, of the gene encoding the wildtype SFV replicase significantly enhances the induction of IFN response in virus infected cells compared to cells infected with wt virus (Breakwell et al. 2007). Thus, mutation RRR>RDR was introduced into the vectors pRSV-Nsp1234, phelF4A1-Nsp1234, and phEF1aHTLV-Nsp1234. The plasmids were named pRSV-RDR, 35 phelF4A1-RDR, and phEF1aHTLV-RDR, respectively.

It is known by literature data that the mutation GDD>GAA in the highly conserved GDD motif of the alphavirus nsP4 (aa 2283-2285 of the SFV Nsp1234) protein completely abolishes the RNA dependent RNA polymerase activity (Tomar et al. 2006). Previously, the GDD>GAA mutation was introduced into the replicase encoded by the vectors pRSV-5 Nsp1234, and pRSV-AAA. The cloned vectors were named as pRSV-GAA, and pRSV-AAA-GAA, respectively. In addition, the GDD>GAA mutation was introduced into the context of the plasmid pEF1aHTLV-Nsp1234, resulting in the vector pEF1aHTLV-GAA. With the intention to construct the control vector with the RRR>RDR mutation in the nsP2 region, the GDD>GAA mutation was introduced into the vector pRSV-RDR resulting in the 10 plasmid pRSV-RDR-GAA.

#### **Example 2: Induction of type I interferon response by RdRp expression**

We used Cop5 mouse fibroblast cell line (ATCC number CRL-1804) as a model cell line to 15 discriminate between different replicase constructs for their ability to induce type I interferon expression. Cop-5 cells were propagated in Iscove's Modified Dulbecco's Medium (IMDM) supplemented with 10% fetal calf serum, 2mM L-Glutamine, and streptomycin-penicillin. Two other human cell lines were also used comparatively – HEK293 and HACAT. Cells were propagated at 37 °C under 5% CO<sub>2</sub> and grown to 50 to 20 70% confluence.

#### ***Transfections***

Electroporation was carried out with a Bio-Rad Gene Pulser. Three plasmid DNA concentrations were used for transfections with 10 ng, 200 ng and 1000 ng and equimolar 25 amounts of control plasmids. All five different constructs were assayed for their ability to induce interferon response: pRSV-Nsp1234, pRSV-RDR, pRSV-AAA, pRSV-RDR-GAA, and pRSV-AAA-GAA. Cells were treated with trypsin, harvested by centrifugation and suspended in growth medium and supplemented with 5mM NaBES. Electroporation was performed in 0.4 mm cuvettes in the presence of 50 ug of carrier DNA (salmon sperm 30 DNA) and left in the cuvette for 15 minutes, washed with growth medium, and seeded on 6-well plates.

#### ***Interferon-β assay***

Cell culture supernatants were harvested 24h, 48h, and 72h after transfection and frozen 35 at -20°C until further analysis using interferon-α and -β kits (PBL Biomedical Laboratories). Cell culture supernatants were appropriately diluted and used in the

enzyme-linked immunosorbent assay according to manufacturer's instructions (PBL Biomedical Laboratories).

### **Results**

5 Levels of interferon- $\beta$  were quantified from collected supernatants by enzyme-linked immunosorbent assay (ELISA) (PBL Biomedical Laboratories) according to the manufacturer's instructions.

### **Conclusions**

10 The generation of interferon response is due to the RNA-dependent RNA-polymerase (RdRp) activity in the compartmentalized RdRp complex. The RdRp effect was completely revoked when the enzymatic activity of RdRp was cancelled out by introducing a GAA mutation into the active centre of the polymerase unit (Fig 2). The interferon expression profile measured from cell culture supernatants after transfection with constructs  
15 containing GAA mutation was similar to construct which does not encode any enzymatic activity (Fig 1, lane paraDMgB).  
On the basis of cell culture experiments, the mutant where the nuclear localization signal (NLS) has been modified in the Nsp2 region by introducing a RDR mutation was chosen as the most promising adjuvant candidate. The mutant with other modifications (AAA) in  
20 the same position of the NLS or wild type RdRp was also assayed for their ability to induce type I interferon response, but with substantially lower effects (Fig 1).  
We also compared the replicase expression vector pRSV-Nsp1234 (SEQ ID NO:5) with the vector pRSV-SFV-Rluc that express both the replicase as well as specific viral cis-sequences containing template RNA. The latter acts as specific substrate for the  
25 replicase. The results of In IFN response induction assay showed that the existence of specific template RNA was not the crucial factor in inducing the interferon response (Fig 3). In human cell lines HEK293 and HACAT we were also able to show specific interferon- $\beta$ , and to a lesser extent, interferon- $\alpha$  induction by pRSV-RDR (Fig 4 and 5).  
30 **Example 3. Accumulation of dsRNA in cytoplasm of replicase expressing cells.**

It is known that dsRNA intermediates are produced during the replication cycle of the SFV genome or the replicase template RNA. The presence of the dsRNA in the cytoplasmic compartment signalling the viral infection to the cell and may lead of the antiviral response  
35 cascade, including the type I interferon response.

As is documented above (Example 2), the SFV replicase expression alone induce the type I interferon response in transfected cells. In addition, it was determined that RdRp

activity of the replicase is critical for the IFN response, because no IFN response was observed after transfection with the expression vectors bearing GDD>GAA mutation that abolish the RdRp activity (Example 2).

Thus, the presence and localization of dsRNA in cells transfected with the replicase expression vectors alone was studied. For this purpose IF analysis using anti-dsRNA monoclonal antibody J2 (Scicons, Hungary) was utilised. This approach was previously used for detection of dsRNA in the cells after infection with +strand RNA viruses (Weber et al 2006). Briefly, the cells were transfected with replicase expression vectors and the next day after transfection the immunofluorescence analysis of paraformaldehyde fixed cells was performed with anti-Nsp1 and anti-dsRNA antibodies (mixed). For signal detection by fluorescence microscopy, secondary antibodies labelled with fluorochromes Alexa488 and Alexa568 and staining the nuclei by DAPI were used.

*Experiment 1.*

15 The RD cells were transfected by PEI-DNA complex with 0.5 ug of phEF1aHTLV-Nsp1234 or with 0.5 ug of phEF1aHTLV-GAA. The results clearly demonstrated that the Nsp1 signal was observed in both cultures. The cytoplasmic dsRNA signal that co-localize with the anti-nsP1 stained spheric patterns was detected in the cells transfected with the phEF1aHTLV-Nsp1234 but not in cells transfected with phEF1aHTLV-Nsp1234-GAA.

20

*Experiment 2.*

The Cop5 cells were transfected by electroporation with 1ug of pRSV-Nsp1234, pRSV-GAA, pRSV-RDR or with pRSV-RDR-GAA. The results shown that although the Nsp1 signal was observed in all cultures, the replicase colocalized cytoplasmic dsRNA was 25 detectable in cells transfected with pRSV-Nsp1234 or pRSV-RDR, but not in cells transfected with the plasmids pRSV-GAA or with pRSV-RDR-GAA.

*Experiment 3.*

30 The RD cells were transfected by PEI-DNA complex with 0.5 or 1 ug of pRSV-Nsp1234, pRSV-AAA or with pRSV-RDR. The results demonstrated that the Nsp1 signal was seen in all cultures. The cytoplasmic dsRNA signal that co-localize with the anti-nsP1 stained spheric patterns was detected in the cells transfected with the pRSV-Nsp1234 or pRSV-RDR but not in cells transfected with pRSV-AAA.

**Conclusion**

It was demonstrated that expression of the wt SFV replicase or the replicase with the mutation RRR>RDR in the nsP2 region, as previously defined herein, induce clear dsRNA accumulation in the cytoplasm of transfected cells that co-localize with the nsp1 positive spheric patterns. In contrast, no such dsRNA accumulation was detected if the cells which were transfected with replicase bearing the GDD>GAA mutation that abolish their RdRp activity.

Thus, these results show correlation between dsRNA accumulation and type I IFN induction by the different replicase mutants. However, no dsRNA accumulation was detected after transfection with the RRR>AAA mutant of the replicase, but induction of type I IFN response was still observed. This may indicate that the induced IFN response is not triggered only by dsRNA signalling, but also by other pathways related to the RdRp activity of the replicase. However, it cannot be excluded that smaller amounts of dsRNA is produced by the replicase mutant RRR>AAA that is not detectable by the used assay conditions.

**Example 4. Adjuvant effect of the expression of the SFV replicase on the cell mediated immune response.**

Three different groups of mice (Balb/c) 5 mice per group) were immunized with gene gun 2 times with 2 week intervals. One microgram plasmid DNA was administrated with both immunizations. The plasmid vector GTU-MultiHIV (encoding selected genes from HIV-1) is an experimental DNA vaccine for HIV-1. When GTU-MultiHIV plasmid was co-administrated with the adjuvants pRSV-Nsp1234 or pRSV-RDR then 0.8 µg GTU-MultiHIV and 0.2 µg adjuvant plasmid were mixed together. For those mice receiving GTU-MultiHIV vector alone, 1 µg plasmid DNA was used. Mice were sacrificed 10 days later. Interferon γ ELISPOT analysis was performed with freshly isolated splenocytes. For stimulating cells one single peptide derived from p24 protein of HIV-1 (AMQMLKETI) was used, which is known to be presented by MHC class I molecules of Balb/c mice. Another stimulant was a pool of overlapping peptides covering the Rev-protein of HIV-1, another component encoded by the DNA-vaccine.

The results indicate that when a DNA vaccine was co-administrated with the vector encoding replicase from SFV, the augmentation of cellular immune response up to 3-fold was observed (Figure 6).

**Example 5. Effect of the SFV replicase expression on the induction of the humoral immune response against the avian influenza virus.**

Three different groups of mice (5 mice per group) were immunized with the plasmid vector 5 pETB-12m-1, encoding HA- and NA-antigens from influenza virus. Mice were immunized in the similar way as in the previous example (1 µg plasmid DNA per immunization, when plasmid was co-administrated with the genetic adjuvant then the ratio 4:1 was used – 800 ng immunizing vector and 200 ng adjuvant vector). Blood samples were analysed for the presence of specific antibodies in ELISA test 2 weeks after the 2<sup>nd</sup> immunization. In this 10 experiment another genetic adjuvant, the vector encoding cytokine GM-CSF, known to boost humoral immune response, was used for comparison.

The results indicate that after two immunizations the best titers were detected in the group where genetic adjuvant pRSV-RDR was mixed with the antigen encoding plasmid. (Figure 7)

15

**Example 6 Adjuvant effect of the expression of the SFV replicase on the cell mediated immune response in mice.**

Three different groups of mice (Balb/c) 4 or 5 mice per group were immunized with gene 20 gun 2 times with 4 week intervals. One microgram of plasmid DNA was administrated with both immunizations. The plasmid vector GTU-MultiHIV (encoding selected genes from HIV-1) is an experimental DNA vaccine for HIV-1. When GTU-MultiHIV plasmid was co-administrated with the adjuvant pRSV-RDR either on the first or the second immunization then 0.8 µg of GTU-MultiHIV and 0.2 µg of adjuvant plasmid were mixed together. For 25 those mice receiving GTU-MultiHIV vector alone, 1 µg of plasmid DNA was used. Mice were sacrificed 10 days after the second immunization. Interferon γ and granzyme B ELISPOT analysis was performed with freshly isolated splenocytes. For stimulating cells one single peptide derived from p24 protein of HIV-1 (AMQMLKETI) and one from Env protein of HIV-1 (RGPGRAFVTI) was used, which are known to be presented by MHC 30 class I molecules of Balb/c mice.

The results indicate that the time of co-administration of the adjuvant SFV replicase has a complex effect on the cellular immune response. Adding adjuvant to the immunization mixture increases interferon gamma response compared to animals who received only 35 GTU-MultiHIV. Different functional capabilities of the cells are revealed after granzyme B expression analysis. Adjuvant augments granzyme B response nearly 3 fold when administered to mice with the first immunization.

## REFERENCES

5 Nature Reviews Microbiology 6, 363-374 (May 2008) "Modification of intracellular membrane structures for virus replication" Sven Miller and Jacomine Krijnse-Locker.

Ahlquist P et al "Host Factors in Positive-Strand RNA Virus Genome Replication" Journal of Virology Aug 2003 vol.77 p8181-8186

10 Blazevic V, Männik A, Malm M, et al. 2006 "Induction of human immunodeficiency virus type-1-specific immunity with a novel gene transport unit (GTU)-MultiHIV DNA vaccine." AIDS Research and Human Retroviruses Vol 22, No 7, pp. 667-677

15 Edwards MR, Slater L, Johnston SL 2007 "Signalling pathways mediating type I interferon gene expression" Microbes and Infection 9, 1245-1251

Medzhitov R "Recognition of microorganisms and activation of the immune response" Nature, Vol 449, 18 October 2007, p.819-826

20 Vercammen E, Staal J, Beyaert R. "Sensing of viral infection and activation of innate immunity by Toll-like receptor 3" Clinical Microbiology Reviews, Jan 2008, p13-25

Darius Moradpour, François Penin, Charles M. Rice 2007 "Replication of hepatitis C virus" Nature Reviews Microbiology 5, 453-463

25 Ventoso I, Sanz MA, Molina S et al 2006 "Translational resistance of late alphavirus mRNA to eIF2a phosphorylation: a strategy to overcome the antiviral effect of protein kinase PKR" Genes and Development 20:87-100.

30 Rautsi et al 2007 "Type I interferon response against viral and non-viral gene transfer in human tumor and primary cell lines". The Journal of Gene Medicine 9:122-135.

Rikkonen et al. 1992. Nuclear and nucleolar targeting signals of Semliki forest virus non-structural protein nSP2. Virology. 189:462-73

35 Agnes LeBon and David F Tough 2002. "Links between innate and adaptive immunity via type I interferon". Current Opinion in Immunology 14:432-436

Theofilopoulos AN et al 2005. "Type I interferons ( $\alpha/\beta$ ) in immunity and autoimmunity".  
Annu.Rev.Immunol 25:307-335

5 Tomar et al. 2006. Catalytic Core of Alphavirus Nonstructural Protein nsP4 Possesses Terminal Adenylyltransferase Activity J Virol. 80 :9962-9

## CLAIMS:

1. Use of an alphaviral replicase, said replicase comprising an RNA dependent RNA polymerase, in the manufacture of an adjuvant for modulating the immune system wherein no alphaviral template RNA containing cis-signals for interaction with the RNA dependent RNA polymerase of the replicase adjuvant is provided for in said adjuvant.

5

2. Use according to claim 1, wherein said alphaviral replicase is a Semliki Forest Virus replicase.

3. Use according to claim 1 or claim 2, wherein said alphaviral replicase is encoded by the sequence set forth in SEQ ID NO:4.

10

4. Use according to claim 2, wherein the amino acid sequence of the replicase corresponds to SEQ ID NO:1.

5. Use according to claim 4, wherein the replicase is mutated in the nsP2 region generating the mutant RRR>RDR in positions 1185-1187 of SEQ ID NO:1.

15

6. Use according to claim 4, wherein the replicase is mutated in the nsP2 region generating the mutant RRR>AAA in the positions 1185-1187 of SEQ ID NO:1.

7. Use according to any one of claims 1-6, wherein said replicase is encoded by an expression vector wherein said expression vector does not express any alphaviral cis-sequences for interaction with the RNA dependent RNA polymerase of the replicase.

20

8. Use according to claim 7, wherein said expression vector is pRSV-RDR, pRSV-AAA, or pRSV-Nsp1234.

9. Use according to claim 7 or claim 8, wherein said vector is a DNA vector.

25

10. Use of an expression vector encoding an alphaviral replicase as defined in any one of claims 1-6 in the manufacture of an adjuvant for modulating the immune system wherein said expression vector does not express any alphaviral cis-sequences for interaction with the RNA dependent RNA polymerase of the replicase.

11. Use according to any one of claims 1-10, wherein said replicase or said expression vector encoding said replicase is formulated together with a pharmaceutically acceptable excipient and/or constituent.

30

12. Use according to any one of claims 1-11, wherein said replicase or expression vector is present in a vaccine composition.

13. Use of an alphaviral replicase as defined in any one of claims 1-9 or 11 as an adjuvant in a vaccine composition for the manufacture of a medicament for the prevention and/or treatment of an infectious disease, wherein no alphaviral template RNA containing cis-signals for interaction with the RNA dependent RNA polymerase of the replicase adjuvant is provided for in said adjuvant.
14. Use according to claim 13, wherein said medicament is used for the prevention and/or treatment of a bacterial disease.
15. Use of an alphaviral replicase or an expression vector as defined in any one of claims 1-11, in the manufacture of a medicament for the prevention and/or treatment of cancer wherein no alphaviral template RNA containing cis-signals for interaction with the RNA dependent RNA polymerase of the replicase medicament is provided for in said medicament.
16. Use according to claim 13, wherein said disease is a viral disease.
17. Use according to claim 16, wherein the viral disease is HIV.
18. Use according to any one of claims 13-17, wherein said medicament comprises a vaccine which is protein-based.
19. Use according to any one of claims 13-17, wherein said medicament comprises an antigen-expressing expression vector encoding one or more antigen(s).
20. Use according to claim 19, wherein said replicase and said one or more antigen(s) are encoded by the same expression vector.
21. Use according to claim 19 or claim 20, wherein said expression vector encoding one or more antigen(s) is a DNA vector.
22. Use according to claim 21, wherein said vector is an expression vector comprising:
  - a) a DNA sequence encoding a nuclear-anchoring protein operatively linked to a heterologous promoter, said nuclear-anchoring protein comprising:
    - i) a DNA binding domain which binds to a specific DNA sequence;
    - ii) a functional domain that binds to a nuclear component; and

b) a multimerized DNA binding sequence for the nuclear anchoring protein,  
wherein said vector lacks an origin of replication functional in mammalian cells.

23. Use according to claim 22, wherein part i) and/or part ii) is obtained from the E2 protein of  
5 the Bovine Papilloma Virus type 1.

24. Use according to claim 23, wherein said one or more antigens of said expression vector  
comprises one or more structural and/or non-structural proteins of HIV.

25. Use according to claim 24, wherein said expression vector encoding one or more  
antigen(s) is GTU-Multi-HIV.

10 26. An expression vector comprising an expression cassette, said expression cassette  
encoding an alphaviral replicase, which replicase essentially corresponds to SEQ ID  
NO:1, and wherein the replicase is mutated in the nsP2 region generating the mutant  
RRR>RDR in positions 1185-1187 of SEQ ID NO:1 wherein said expression vector does  
not express any alphaviral cis-sequences for interaction with the RNA dependent RNA  
15 polymerase of the replicase.

27. An expression vector according to claim 26, comprising an expression cassette  
comprising a sequence essentially as disclosed in SEQ ID NO:4, wherein a mutation has  
been introduced into positions 4129-4131 of SEQ ID NO:4, generating when expressed  
the mutant RRR>RDR in positions 1185-1187 of SEQ ID NO:1.

20 28. An expression vector according to claim 27, wherein said expression vector is pRSV-  
RDR.

29. An expression vector according to any one of claims 26-28, for use as a medicament.

30. A nucleic acid sequence essentially corresponding to SEQ ID NO:4 wherein the mutation  
CGG to GAC has been introduced into positions 4129-4131 of SEQ ID NO.4 wherein said  
25 nucleic acid sequence does not contain any alphaviral cis-sequences for interaction with  
the RNA dependent RNA polymerase of the replicase.

31. A method of modulating the immune system said method comprising the step of  
administering to a subject in need thereof an alphaviral replicase as an adjuvant, said  
replicase comprising an RNA dependent RNA polymerase wherein said method does not  
comprise administering viral template RNA containing cis-signals that interact with said  
30 RNA dependent RNA polymerase.

32. A method of modulating the immune system said method comprising the step of administering to a subject in need thereof an expression vector as defined in claim 10 wherein said method does not comprise administering viral template RNA containing cis-signals that interact with said RNA dependent RNA polymerase and wherein said replicase encoded by said administered expression vector is provided as an adjuvant.
- 5
33. A method of preventing and/or treating an infectious disease said method comprising the step of administering to a subject in need thereof an alphaviral replicase or an expression vector as defined in any one of claims 1 to 11 wherein said method does not comprise administering viral template RNA containing cis-signals that interact with said RNA dependent RNA polymerase and wherein said replicase is administered as an adjuvant.
- 10
34. A method of preventing and/or treating cancer said method comprising the step of administering to a subject in need thereof an alphaviral replicase or an expression vector as defined in any one of claims 1 to 11 wherein said method does not comprise administering viral template RNA containing cis-signals that interact with said RNA dependent RNA polymerase and wherein said replicase is administered as an adjuvant or said replicase encoded by said administered expression vector is present as an adjuvant.
- 15
35. Use according to any one of claims 1 to 25; an expression vector according to any one of claims 26 to 29; a nucleic acid sequence according to claim 30; or a method according to any one of claims 31 to 34, substantially as herein described with reference to any one or more of the examples but excluding comparative examples.
- 20




Fig.1




Fig.2




Fig.3




Fig.4




Fig.5




Fig.6




Fig.7




Fig.8




Fig.9